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Classically activated macrophages produce high levels of IL-12 and moderate 
levels of IL-10.  When IgG immune complexes ligate the Fcγ receptors on activated 
macrophages, they shut off IL-12 synthesis and increase IL-10 production.  These 
macrophages are termed ‘type II’ activated macrophages.  The anti-inflammatory 
responses of type II activated macrophages could be harmful to the host when an 
inflammatory response is critical to pathogen clearance.  The clearance of 
intracellular pathogens, such as Leishmania spp., relies upon an inflammatory 
response.  Inflammatory cytokines lead to classical macrophage activation, which is 
critical to the destruction and clearance of phagocytosed parasites.  Without a robust 
inflammatory response, Leishmania parasites are free to replicate within 
macrophages, leading to disease pathology.  Based on this knowledge, it was 
hypothesized that IgG coated Leishmania amastigotes would ligate Fcγ receptors on 
host macrophages and induce the production of IL-10.  Therefore, the role of IgG in 
mediating host defense to Leishmania was examined.  For these studies, JH mice, 
which lack IgG and are on the Leishmania major susceptible BALB/c background, 
  
were used.  We show that IgG not only fails to provide protection against this 
intracellular pathogen, but it actually contributes to disease progression.  JH mice 
were more resistant to disease than control BALB/c mice, and reconstitution with α-
L. major antisera resulted in increased disease, with larger lesions and higher numbers 
of parasites.  Antibody administration correlated with an increase in IL-10 production 
in lesions, however, this IgG mediated exacerbation of disease could be reversed by 
simultaneously treating with α-L. major antisera and a monoclonal antibody against 
the IL-10 receptor.  The α-L. major IgG profiles of resistant C57BL/6 mice and 
susceptible BALB/c mice were examined.  BALB/c mice exhibited higher levels of 
IgG, in both circulating titers and on the surfaces of amastigotes, than C57BL/6 mice.  
The differences in the α-L. major IgG titers between resistant and susceptible strains 
provide evidence of the integral role of IgG during leishmaniasis.  These studies 
demonstrate that IgG can cause a novel form of immune enhancement due to its 
ability to induce IL-10 production from macrophages.   
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CHAPTER 1: INTRODUCTION 
 
INNATE IMMUNITY 
Overview 
The immune system is divided into innate and acquired components, 
each with distinct immunological functions.  Innate immunity is 
phylogenetically the oldest mechanism of defense against infection, and is 
present in all multicellular organisms1.  Acquired immunity relies upon T and 
B lymphocytes, and their ability to recognize a large number of diverse 
antigens, based on their individual expression of rearranged antigen receptors.  
Following antigen recognition, lymphocytes are activated and proliferate in a 
process termed clonal expansion.  Although this process is necessary for an 
efficient immune response, the time required for lymphocyte expansion and 
differentiation to occur allows pathogens to infect and damage the host.  This 
window of susceptibility is covered by innate immunity2.   
Innate immunity is the first line of defense.  It is rapidly activated by 
microbes, and in some situations, it can eliminate them.  The effectors of 
innate immunity, composed primarily of complement, cytokines, neutrophils, 
macrophages (Mφ), and natural killer (NK) cells, are immediately available 
upon encountering an antigen.   
The cells of the innate immune system have inheritable germ line 
encoded ‘pattern recognition receptors’, which allow these cells to recognize a 
number of highly conserved patterns that are associated with microorganisms 
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exclusively.  These patterns, termed pathogen associated molecular patterns 
(PAMPs)3, include lipopolysaccharide (LPS), lipoteichoic acid (LTA), 
peptidoglycan, unmethylated CpG nucleotides, and mannans.  These 
molecules are characteristics of microbial pathogens, and are not typically 
found on mammalian cells.  This allows the components of the innate immune 
response to distinguish between self and non-self.  Because these molecules 
are essential to microbial survival, the microbes cannot simply discard them in 
an attempt to go unnoticed by the immune system. 
These pattern recognition receptors are found on many effector cells of 
the innate immune system, and their expression is not clonal.  Pattern 
recognition receptors fall into three categories, secreted, endocytic, and 
signaling.  Secreted receptors, such as mannan-binding lectin, opsonize 
microorganisms and allow for recognition by complement and phagocytes.  
Endocytic receptors, such as the macrophage mannose and scavenger 
receptors, are expressed on the surface of phagocytes.  These receptors 
recognize PAMPs and bind the organism for uptake and delivery to the 
lysosome2.  Signaling receptors, such as toll-like receptors (TLRs)4, recognize 
PAMPs and activate signal transduction pathways that induce the expression 
of genes involved in the immune response against the microorganism.  TLRs 
also induce the upregulation of co-stimulatory molecules, which provide the 
secondary signal necessary for the activation of the cells of the adaptive 
immune response (Figure 1).  Thus, the adaptive response depends on innate 
immunity, and only occurs after a pathogen has first been detected by the  
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innate immune system.  Through the recognition of microbes and the 
activation of signal transduction pathways, the innate immune system triggers 
and controls the major aspects of the adaptive immune response2. 
 
Macrophages 
Macrophages have a central role in both the innate and adaptive 
immune responses, and are important for the elimination of microbes.  They 
can be found at all the sites where a microbe could gain entry to the host, and 
are resident in the liver, spleen, subepithelial connective tissue, lymphatics, 
and the interstitial of parenchymal organs.  These cells express a variety of 
surface receptors, such as Fcγ, complement, scavenger, TLRs, and mannose, 
which allow efficient binding and phagocytosis of pathogens.  Microbes are 
ingested into phagosomes, which subsequently fuse with lysosomes to create 
phagolysosomes.  Inside the phagolysosomes, microbes come into contact 
with proteolytic enzymes, as well as a lowered pH, which contribute to the 
destruction of the organisms.  Certain pathogens avoid killing by preventing 
phagosomes-lysosome fusion (T.gondii), preventing phagolysosome 
acidification (Chlamydia spp.), escaping into the cytosol (L. monocytogenes), 
or thriving in acidified vacuoles (Leishmania spp.)5. 
Opsonization with immunoglobulin G (IgG), in most cases, targets 
particles to Fc receptors, where they enter phagolysosomes, trigger a 
respiratory burst, and are destroyed6.  The Fc receptor (FcR) is composed of a 
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region that binds the Fc portion of antibody molecules, called the α chain, 
associated with one or more signal transduction regions, the β and γ chains.  
The γ chain is a 7 kD polypeptide that is homologous to the ζ chain of the T 
cell receptor.  There are three different receptors for the Fc portion of IgG, 
termed Fc γ receptors (FcγRs).  These receptors play a critical role in many 
immune responses, such as phagocytosis, respiratory burst, cytokine 
production, and clearance of immune complexes7.  FcγRI, also known as 
CD64, is the high affinity receptor, and can bind monomeric IgG.  In the 
human system, this receptor binds IgG1 and IgG3 tightly, while in the mouse, 
IgG2a and IgG2b are tightly bound.  FcγRII and FcγRIII, also known as CD32 
and CD16 respectively, are low affinity receptors which bind poorly, if at all, 
to monomeric IgG, but can bind IgG coated antigens.  In July 2005, it was 
reported that a fourth FcγR existed, which was termed FcγRIV8.  FcγRIV 
expression is restricted to myeloid cells, and it binds IgG2a and IgG2b 
exclusively.  This receptor was discovered after it was observed that mice 
deficient in the α subunit of the FcγR, which binds the IgG, of the known 
activation FcγRs (FcγRI and FcγRIII), displayed either partial or no reduction 
in the ability to trigger effector cell responses9-11.  This suggested that IgG was 
still binding, and that other γ-chain dependent FcγR α subunits were involved 
in the in vivo activity of IgG2a and IgG2b.  These data suggest an important 
role for FcγRIV in IgG2a and IgG2b induced inflammatory responses, and 
shows the powerful influence that these two isotypes have over protective and 
pathogenic properties8. 
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Macrophage Activation 
 Macrophage activation was first described in 196412, showing that the 
infection of mice with Mycobacterium bovis bacillus Calmette-Guerin (BCG) 
or Listeria monocytogenes enhanced the antimicrobial activities of 
macrophages.  LPS and interferon γ (IFN-γ) are the stimuli responsible for this 
type of macrophage activation, known as ‘classical’ activation of 
macrophages.  Since the discovery of macrophage activation, it has become 
clear that there is more than one way to activate a macrophage.  The different 
modes of macrophage activation, lead to the development of different 
populations of macrophages with distinct biological functions.  There 
currently appear to be at least three populations of activated macrophages, the 
classical, alternative, and type II activated macrophages.  
  
The classically activated macrophage was discovered first, and is the 
most well described of the three populations.  The classical activation of 
macrophages is dependent upon two signals, IFN-γ and tumor necrosis factor 
(TNF), or an inducer of TNF.  IFN-γ primes macrophages for activation13.  
TNF itself can act as the second signal, but generally the second signal is a 
result of TLR ligation, which induces the production of TNF by the 
macrophage.  Once activated, these cells upregulate surface molecules such as 
major histocompatibility complex (MHC) class II and B7, which allows them 
to be effective antigen presenting cells.  These cells also secrete a myriad of 
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inflammatory cytokines including, interleukins (IL) 1, IL-6, IL-12, and TNF, 
which enhances their ability to kill intracellular organisms.  Activated 
macrophages accomplish the killing of phagocytosed organisms by increasing 
the production of toxic oxygen species, and activation of inducible NO 
synthase (iNOS).  Thus, the classically activated macrophage is invaluable in 
the clearance of pathogens.  However, this inflammation must be carefully 
regulated, lest injury to the host occur.  When activated macrophages are left 
unchecked, the excessive inflammation can lead to tissue destruction, 
autoimmune diseases, and chronic granuloma formation14. 
 
The alternatively activated macrophage was described in 199215, when 
it was noticed that IL-4 induced the expression of the mannose receptor on 
these macrophages.  These macrophages showed signs of activation, but the 
activation profile was different than that of classically activated macrophages.  
Thus, macrophages treated with IL-4 were ‘alternatively’ activated.  These 
cells do not produce NO, and are ineffective at killing phagocytosed microbes.  
Although these cells moderately upregulate MHC II, they aren’t effective in 
antigen presentation.  Rather than the inflammatory cytokines secreted by 
classically activated macrophages, alternatively activated macrophages 
produce IL-10 and IL-1 receptor antagonist, and have been described by some 
as having regulatory functions16.   
Using the murine model of Schistosoma mansoni, it was discovered 
that when macrophages are treated with Th1 cytokines, the iNOS2 enzyme 
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produced NO from arginine.  However, exposing macrophages to Th2 
cytokines induces Arg-1, which metabolizes arginine to yield urea and 
ornithine17.  These products give rise to polyamines, which are important in 
cell proliferation, and proline, which leads to the production of collagen.  The 
production of polyamines and proline, which in turn cause cell proliferation 
and collagen production, suggests that these cells may also be involved in 
wound and tissue repair18.  Therefore, alternatively activated macrophages are 
important for regulatory and repair functions, in stark contrast to the 
inflammation induced by classically activated macrophages. 
 
The type II activated macrophage was described in 199719, during an 
investigation into the termination of IL-12 upon FcγR ligation.  It was later 
revealed that by ligating FcγRs on macrophages, the production of the 
proinflammatory cytokine IL-12 is terminated, and the production of the anti-
inflammatory cytokine, IL-10, is induced20.  The name ‘type II’ activated 
macrophage is indicative of their ability to induce Th2 immune responses21.  
Like the classically activated macrophage, type II activated macrophages also 
require two signals.  The first signal required is the FcγR ligation, which is 
accomplished by the binding of IgG opsonized antigens.  The receptor ligation 
must be coupled with a second, stimulatory signal, necessary for cytokine 
production.  The cytokine switch occurs in both primed and unprimed 
macrophages.  This cell is biologically distinct from the classically activated 
as well as the alternatively activated macrophages, and does not induce 
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arginase.  The switch from IL-12 to IL-10 is dramatic, while the secretion of 
other cytokines, such as TNF, IL-1, and IL-6, is not affected21;22. 
This profound cytokine reversal from proinflammatory to anti-
inflammatory response was found to rescue mice from LPS toxicity.  This 
effect was shown to be directly related to the secretion of IL-10 by utilizing 
macrophages from IL-10-/- mice.   IL-10-/- macrophages were unable to rescue 
mice from endotoxemia21;23.  Thus, the type II activated macrophage has 
potent anti-inflammatory properties.   
The type II activated macrophage was also shown to influence 
antibody responses in mice24.  In these studies, mice were injected with either 
classically, or type II activated macrophages, along with ovalbumin (OVA) 
antigen.  Mice treated with OVA and classically activated macrophages made 
a modest antibody response to antigen.  However, when mice were treated 
with OVA and type II activated macrophages, IgG levels increased 
significantly.  It was determined that the majority of IgG produced was of the 
IgG1 isotype, and that type II activated macrophages were able to induce IgG 
class switching.  These studies demonstrated the ability of type II activated 
macrophages to induce the production of IL-4 from T cells, which then 
induced B cells to produce IgG1.  Thus, type II activated macrophages have 
powerful anti-inflammatory properties, and are strong inducers of Th2 
responses. 
The anti-inflammatory responses produced by type II activated 
macrophages could be potentially harmful in instances where an inflammatory 
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response is critical to the host survival.  Infections with intracellular pathogens 
are demonstrative of this point.  The clearance of intracellular pathogens, such 
as infections with Leishmania spp., is reliant upon a robust inflammatory 
response.  Inflammatory cytokines, such as IL-12 and IFN-γ, lead to the 
classical form of macrophage activation.  This activation is critical to the 
destruction and clearance of phagocytosed pathogens.   
The ligation of FcγRs with IgG coated pathogens shuts off the 
production of IL-12 and induces the production of IL-10 from macrophages.  
This reversal in cytokine production blocks the inflammatory response and 
biases toward an anti-inflammatory response.  Without a robust inflammatory 
response, Leishmania parasites are free to replicate within host macrophages, 
leading to disease pathology.  Thus, while type II activated macrophages are 
important players of the immune system, they could also potentially cause 
harm to the host during infections with intracellular pathogens. 
 
Cytokines 
 Cytokines, which are also commonly referred to as interleukins, are 
proteins produced and secreted by the cells of innate and adaptive immunity in 
response to microbes and antigens.  Though there are many cytokines, which 
mediate a diverse array of biological effects, they share several important 
properties.  Cytokines can be pleiotropic, redundant, synergistic, and 
antagonistic.  Being pleiotropic allows a single cytokine to influence several 
cell types, leading to diverse biological effects.  Many cytokines have the 
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same biological effect, demonstrating a redundancy that allows for immune 
function in cases of a single cytokine gene knockout, or an antagonist against 
a single cytokine.  Cytokines can be synergistic, with two or more cytokines 
working in concert to produce a greater biological effect, or antagonistic, with 
one cytokine inhibiting the effects or synthesis of another1.  Cytokines are 
important for both innate (IFN-γ, TNF, IL-1, IL-10, IL-12) and adaptive (IFN-
γ, IL-2, IL-4, IL-5) immunity. 
 
IFN-γ, IL-12, and IL-10 are important during infection, and function to 
initiate and regulate the innate immune response to pathogens.  During an 
infection, IL-12 is rapidly produced and is an important proinflammatory 
cytokine of the early innate response.  IL-12 is a heterodimeric protein made 
up of two disulfide-linked subunits designated p35 and p40, representing their 
approximate molecular weights25.  Studies involving animal models 
demonstrate the central role IL-12 plays in providing protection from various 
diseases.  Infection of IL-12 p40-/- mice with Mycobacterium tuberculosis 
leads to decreased resistance to the disease26.  Decreased resistance, due to a 
lack of IL-12, has also been shown with Listeria monocytogenes27;28, 
Toxoplasma gondii29, Cryptococcus neoformans30 and Leishmania major31. 
IL-12 plays a key role in stimulating the production of IFN-γ from T-
cells and NK cells.  The production, and subsequent secretion, of IFN-γ acts to 
activate macrophages, providing a powerful feedback mechanism.  These 
activated macrophages are now able to increase IL-12 production, resulting in 
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a proinflammatory loop32.  IL-12 has been shown to induce the production IL-
1033, which can inhibit the production of IL-1234, thus providing negative 
feedback for regulating the proinflammatory response. 
 
IFN-γ  is a homodimeric protein produced by NK, CD4+ Th1, and 
CD8+ T cells, primarily in response to IL-12.  It is responsible for activating 
macrophages, and it plays a critical role in both innate and adaptive immunity.  
IFN-γ stimulation results in macrophages that display increased pinocytosis 
and receptor mediated phagocytosis as well as enhanced microbial killing 
ability.  It has been shown to play a role in host defense against non-
tuberculosis Mycobacteria35, Leishmania, Toxoplasma, Rickettsia, and 
Chlamydia36. 
IFN-γ-activated microbicidal ability includes induction of TNF, the 
NADPH-dependent phagocyte oxidase (NADPH oxidase) system (respiratory 
burst), NO production, and up-regulation of lysosomal enzymes promoting 
microbe destruction37.  In addition, granuloma formation, and the upregulation 
of costimulatory molecules and MHC class I and II on antigen presenting cells 
(APCs), are also stimulated by IFN-γ38.  The net effect of these responses is to 
create a macrophage-rich inflammatory response. 
 
 IL-10 is a noncovalent homodimer that is acid sensitive39.  IL-10 is a 
potent anti-inflammatory cytokine, and acts to limit an excessive 
inflammatory response, in order to avoid inflammation related pathology.  It 
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affects cytokine production, soluble mediators, and cell surface molecules, 
having profound effects on the ability of immune effector cells to initiate and 
sustain an immune response.  IL-10 blocks production of chemokines that are 
involved in inflammation40, and in addition enhances expression of their 
antagonists41.  IL-10 inhibits the activation of macrophages.  Since it is 
produced by activated macrophages, it is an example of negative feedback in 
the regulation of immunity.  Thus, IL-10 functions in the termination of the 
inflammatory state, and the return to a resting state, as a microbial infection is 
cleared.   
 IL-10 enhances the expression of FcγRs, specifically CD16 and CD64, 
on monocytes42;43.  Upregulation of the FcγRs by IL-10 correlates with 
enhanced phagocytosis of opsonized particles44, but a reduced ability to kill 
ingested organisms45.  Ligation of FcγRs also induces the production of IL-10, 
therefore suggesting another regulatory mechanism where IL-10 upregulates 
FcγR expression, and their subsequent ligation induces enhanced IL-10 
production and a termination of the inflammatory response20. 
 The inhibitory effects of IL-10 on inflammation suggest that it could 
lead to the inhibition of the inflammatory response during infection in vivo46, 
and in fact, IL-10 was shown to rescue BALB/c mice from LPS induced toxic 
shock47.  During the administration of endotoxin, IL-10 was shown to be 
induced in several animals including mice48, chimpanzees49, as well as in 
humans50.  IL-10 production during the administration of endotoxin reduced 
the levels of IFN-γ51, and regulated leukocyte-endothelial cell interactions and 
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microvascular permeability52.  IL-10 production during septicemia can be 
correlated to the intensity of the inflammatory response, severity of injury, 
and clinical outcome53-55.  These observations suggest that IL-10 plays an 
important role in the regulation of systemic inflammation.   
 High levels of IL-10 have been thought to predispose a person to 
systemic lupus erythematosus (SLE), and precede onset of the disease56.  An 
increased rate of mortality in meningococcal disease is also associated with a 
genetic predisposition of a higher level of IL-10 expression57.  IL-10 gene 
homologs have been found in the genomes of several viruses, such as Epstein-
Barr (EBV)58, human cytomegalovirus (CMV)59, and equine herpes virus type 
260.  Except for CMV, the conservation of the amino acid sequence between 
viral (vIL-10) and human (hIL-10) IL-10 is 84%.  Almost all anti-hIL-10 
antibodies cross react with vIL-1061.  The capture of an IL-10 gene by a virus, 
which could then be evolved to suit its needs in terms of host interaction, 
could be extremely beneficial to viral survival, especially considering the 
deactivating effects of IL-10 on the inflammatory response. 
 EBV vIL-10 is able to mimic some functions of IL-10, such as 
macrophage deactivation62.  The ability of EBV to express vIL-10 indicates 
that it may be beneficial to the survival of the virus.  vIL-10 is expressed 
during the lytic phase63.  A target cell of vIL-10 is the macrophage, which is 
relevant during the lytic phase.  vIL-10 is able to inhibit macrophage 
activation, which suppresses an anti-viral immune response and allows the 
virus to establish latency46.   
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 During infection, the immune system must respond to, and clear, a 
pathogen while minimizing damage to the host.  IL-10 plays a significant role 
in helping to maintain the delicate balance between protecting the host from 
pathogens, and also from excessive inflammation.  The anti-microbial effects 
of the inflammatory immune response can cause damage to the host that is 
often more destructive than the infection.  Excessive inflammation can lead to 
damage ranging from localized destruction of infected cells to widespread 
tissue necrosis, and chronic granuloma formation46.  These effects can have 
life threatening consequences when critical tissues, such as cardiac muscle, 
are involved.  A systemic response to microbes can also lead to sepsis, which 
can result in death.  Thus, ironically, the efficient clearance of an infection 
could ultimately lead to the demise of the host.  IL-10 plays a vital role in the 
regulation of the inflammatory response to pathogens, and in protecting 
against inflammation related pathology. 
 Manipulating IL-10 levels during infections in animal models, 
demonstrated the crucial role IL-10 plays in the regulation of pathology and 
protection.  Normal levels of IL-10 can impair the immune response to 
pathogens, and experiments in animal models have shown that by reducing 
IL-10, resistance to infection is almost always improved46.  If IL-10 levels are 
increased during infection, using rIL-10, mice are more susceptible to 
intracellular pathogens such as L. monocytogenes64, Streptococcus 
pneumoniae65, Candida albicans66, and Trypanosoma cruzi67.  However, if IL-
10 levels are reduced during infection, mice are more resistant to the 
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intracellular pathogens listed previously65;68-70, as well as T. gondii71, and L. 
major72.  There is also strong evidence that supports the role of IL-10 in 
human diseases such as visceral leishmaniasis73;74, leprosy75, malaria76, and 
tuberculosis77.   
 
 
ADAPTIVE IMMUNITY 
Overview 
 The adaptive immune response is comprised of lymphocytes and their 
products, and is more highly evolved than the innate response.  When 
stimulated by a pathogen, the adaptive immune response is able to adapt and 
mount an appropriate response based on the characteristics of a particular 
organism.  The innate and adaptive immune responses work together to 
protect the host from infectious organisms.  The innate immune response 
encounters pathogens and initiates a response, which in turn stimulates 
adaptive immunity.  The adaptive immune response then uses the effector 
molecules of innate immunity to eliminate the infection, frequently by 
enhancing the microbicidal functions of the innate response.  The defining 
characteristics of the adaptive response are its specificity, and its ability to 
remember and later respond to repeated exposures of that pathogen more 
vigorously.   
 The fundamental properties of the adaptive immune response are 
specificity, diversity, specialization, self-limitation, memory, and non-
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reactivity to self.  Specificity ensures that a particular antigen elicits the 
appropriate, specific response.  Lymphocytes express membrane receptor that 
distinguish between various antigens.  When a receptor encounters its specific 
antigen, it responds and that particular clone proliferates.  This process is 
termed clonal expansion.  Diversity refers to the number of antigenic specific 
lymphocytes, which is termed the lymphocyte repertoire.  The immune system 
can respond to 109-1011 antigen specific epitopes, allowing an antigen specific 
response to a large number of pathogens.  The distinct way the immune 
system responds to different organisms is termed specialization.  These 
responses are specialized to the microbe, in order for optimal host defense.  
Self-limitation is the return to homeostasis.  After encountering an organism, 
the immune response is regulated, and returns to its resting state.  Memory 
develops after exposure to an antigen, and allows for enhanced responses 
upon subsequent exposures of the same antigen.  These secondary immune 
responses are larger, and occur faster than the primary response.  Non-
reactivity to self is one of the most important and remarkable features of 
adaptive immunity.  This prevents the injury and attack of host cells from its 
own lymphocytes, and is also referred to as self-tolerance.  Problems with the 
maintenance of self-tolerance often lead to the development of autoimmune 
diseases.  These hallmarks of adaptive immunity are essential to the function 
of host defense. 
 The adaptive response is composed of three phases, recognition, 
activation, and effector.  During the recognition phase, a lymphocyte receptor 
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encounters its specific antigen, and undergoes clonal expansion.  Clonal 
expansion yields numerous lymphocytes from a single clone, which are 
capable of reacting with a specific antigen.  The activation phase requires two 
signals, the antigen itself and either microbial products or components of the 
innate response to the microbe.  This two-signal requirement ensures that 
activation occurs only when needed, and that it is specific to the antigen.  The 
activation phase involves the synthesis of proteins, cellular proliferation, 
differentiation into effector cells that function to eliminate antigens, or 
differentiation into memory cells that provide enhanced responses to 
subsequent exposures.  During the effector phase, activated lymphocytes 
perform the functions needed in order to eliminate organisms.  This phase 
often involves the cooperation of innate and adaptive immunity for effective 
clearance of the organism.   
 There are two types of adaptive immune responses, humoral and cell 
mediated.  These two responses are mediated by different immune cells, and 
eliminate different types of organisms.  Cell mediated immunity is mediated 
by T lymphocytes, and is also known as cellular immunity.  This response is 
generated against intracellular microbes, which survive and proliferate inside 
host cells.  Cell mediated immunity leads to the destruction of the microbes, 
or the lysis of the infected cells.  Humoral immunity is mediated by antibodies 
in the blood, which are produced by B lymphocytes.  Antibodies specifically 
bind to antigens, neutralizing their infectivity and targeting them for 
elimination by other effector mechanisms, such as complement and 
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phagocytosis.  This response is generated against extracellular microbes and 
their toxins.   
 Immunity against a microbe can be induced by the host’s own immune 
response, or by the transfer of microbe specific antibodies or lymphocytes.  
Immunity induced by the host’s immune response against exposure to a 
microbe is termed active immunity.  This is because the host’s immune 
response played an active role in responding to, and clearing, the microbe.  
Immunity can also be induced by the transfer of serum (antibodies) or 
lymphocytes from an immunized individual.  This process is known as 
adoptive transfer, and results in immunity without exposure to the microbe.  
Since the host’s immune response plays no active role in conferring this 
immunity, it is known as passive immunity.  Passive immunity provides rapid 
resistance, since there is no wait for an active immune response to develop.  
Both types of immunity are antigen specific and provide resistance to 
infection, but only active immunity leads to the development of memory cells.   
 
T cells 
T cells originate in the bone marrow and mature in the thymus.  T cells 
exhibit specificity when recognizing antigen due to the polymorphic T cell 
receptor (TCR).  The TCR undergoes gene rearrangement during maturation 
in the thymus.  This process results in a TCR specific for a single antigen, and 
commits the TCR to this specificity for the remainder of the life span.  T cells 
recognize their specific antigen only when presented as a processed peptide.  
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These peptides are loaded onto the MHC expressed on antigen presenting 
cells (APCs)78.  Since recognition of antigen is dependent upon MHC 
recognition, T cells must be selected for their ability to engage MHC during 
the maturation process.  T cells are first selected for their ability to recognize 
self MHC in a process known as positive selection79.  T cells then undergo 
negative selection, which involves the apoptosis of T cells which react to self 
antigens80.  This step is important for self tolerance and ensuring that the 
adaptive immune response is not initiated against the host.   
T cells are further divided into individual subsets which direct distinct 
responses.  These cells differ in their mutually exclusive expression of either 
CD4 or CD8.  The subsets are referred to as CD4+ helper T cells, and CD8+ 
cytotoxic T cells.  CD4 and CD8 determine which MHC complex can interact 
with the T cell.  CD4+ T cells are restricted to interaction with the MHC class 
II, while CD8+ T cells are restricted to MHC class I.  CD8+ T cells mature in 
to cytotoxic T lymphocytes (CTLs) which function in the lysis of pathogen 
infected cells.  CTLs have cytolytic proteins that allow for the destruction of 
targeted cells.  CD4+ T cells are further divided into distinct subsets based on 
their function and cytokine production.  These cells initiate, maintain, and 
regulate the humoral and cell mediated immune responses81. 
There are two distinct subsets of CD4+ helper cells (Th1 and Th2), and 
a subset of T regulatory (Treg) cells, and which are defined based on their 
cytokine production82.  The T helper cell subsets enhance, or ‘help’, in the 
innate, cellular, and humoral responses to antigens, and are defined by the 
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cytokines they produce.  Th1 cells are defined by their production of IL-2 and 
IFN-γ, while Th2 cells produce IL-4 and IL-5.  Th1 responses are 
characterized as being inflammatory, and help in the clearance of intracellular 
pathogens.  Conversely, Th2 responses are characterized as anti-
inflammatory, and function in the control and clearance of extracellular 
pathogens and helminths.   T regs are characterized by the production of IL-10 
and TGFβ, and function to control the immune response83. 
 Activation and clonal expansion of T cells occurs in response to two 
signals.  The first signal is the recognition of antigen by the TCR.  This must 
occur simultaneously with the second signal, the recognition of co-stimulatory 
molecules on the surface of the APC84.  The maturation process of T cells 
involves the development of memory cells.  Memory cells are a sub 
population of clonally expanded, long lasting, T cells that revert to a quiescent 
state85.  Maximum efficiency in responding to pathogens is achieved by 
preferentially recirculating naïve cells through the secondary lymph organs, 
while memory cells remain in the peripheral tissues and blood86. 
 
B cells 
 B lymphocytes are an important part of adaptive immunity, and are 
capable of producing and secreting millions of antigen specific antibodies.  
Antibodies have a common core structure of two identical covalently linked 
heavy chains and two identical light chains, each of which is linked to one of 
the heavy chains.  Each antibody recognizes a different antigen, and their 
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diversity is due to the complex mechanism of V(D)J recombination of the 
immunoglobulin genes87, as well as somatic hypermutation, and class 
switching.  B cells recognize antigen via the B cell receptor (BCR), which is 
composed of two immunoglobulin (Ig) heavy chains, two Ig light chains, and 
two heterodimers of Igα and Igβ88.   
 B cells originate and mature in the bone marrow, and are the only cells 
capable of differentiating into plasma cells, which produce antibodies.  An 
important characteristic that sets them apart from T lymphocytes is their 
ability to recognize soluble antigen.  Immature B cells develop into mature B 
cells, which express IgM and IgD on their surface.  This is a tightly controlled 
process, with approximately 75% of developing cells becoming apoptotic 
during pre-B cell development89.  Apoptosis is induced if heavy chain gene 
rearrangement is incomplete or inappropriate.  
 During maturation, the immunoglobulin genes undergo rearrangement, 
allowing for production of a unique receptor on each cell.  This gene 
rearrangement allows an individual to produce approximately 1011 distinct 
antibody specificities88.  Apoptosis may also be induced at this point if the 
surface Ig recognizes and responds to self-antigens.  This induction of 
apoptosis is known as negative selection.  Antigen binding is required for 
activation, and B cells can become activated on their own in response to non-
protein antigens (T-independent), or with the help of T cells in response to 
protein antigens (T-dependent).  In addition to antigen binding, the activation 
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of B cells also requires a second signal which is fulfilled by the binding of 
complement protein C3d to the type II complement receptor (CR2)1.   
 During activation, B cells become enlarged, and undergo clonal 
expansion.  Co-receptors are important during activation, and provide 
regulation of B cell signaling.  CD40 is essential for T-dependent antibody 
responses, while CD22 and the FcγRIIB inhibit B cell activation.  Following 
proliferation, some B cells will undo differentiation into plasma and memory 
cells.  Plasma cells produce antibodies, and exhibit a large endoplasmic 
reticulum and Golgi appartatus, which are necessary in the production of 
antibody.  Since plasma cells produce only secreted antibody, Ig mRNAs 
increase, while surface Ig expression decreases.   
 Two major genetic changes occur during differentiation, somatic 
mutations and class switching.  Somatic mutations change the antigen binding 
properties, allowing antigens to bind more tightly to B cells.  Class switching 
results in a change in the heavy chain constant region within the 
immunoglobulin, and affects the way B cells and antibody are recognized by 
effector cells89.   
 The main function of B cells is to produce and secrete antibodies.  
Antibodies protect in several ways, including, neutralizing toxins, preventing 
the invasion of viruses and bacteria into cells, and coating antigens to enhance 
phagocytosis, as well initiate the complement cascade.  There are 5 classes of 
Ig (IgM, IgD, IgA, IgG, and IgE).   
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 IgM and IgD are found on the surface of B cells.  IgD is not secreted, 
and is only found as an antigen receptor on naïve B cells.  IgM is expressed on 
the surface of B cells, as well as secreted, and is the first class of Ig to be 
expressed after antigen binding.  It is secreted as a pentamer, and subsequently 
is particularly good at activating the complement cascade.  IgA functions in 
mucosal immunity, and is secreted as a monomer, dimmer, and trimer.  IgE is 
secreted as a monomer, and functions in immediate hypersensitivity reactions 
and the eosinophil mediated killing of helminths.  IgG is secreted as a 
monomer, and functions in opsonization, feedback inhibition of B cells, 
complement activation, and antibody-dependent cytotoxicity1.  The class 
switching of antibody molecules allows for changes in the antibody, while still 
retaining its specificity. 
 Changes in the isotypes of antibodies during a humoral response allow 
a single clone of B cells to produce antibodies with identical specificity for 
antigen, but different functions.  These changes in isotypes are referred to as 
isotype switching, and influence how the antibodies work to eradicate antigen.  
The cytokine environment heavily influences class switching.  Cytokines play 
an important role in antibody production, with different cytokines having 
distinct, but frequently overlapping roles.  These cytokines not only influence 
isotype switching, but also have significant impact on the production of 
various subclasses of Ig isotypes, such as IgG (Table 1).  In humans, the IgG 
isotype can be further divided into subclasses known as IgG1, IgG2, IgG3, 
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and IgG4.  The IgG isotype of mice can also be subdivided into IgG1, IgG2a, 
IgG2b, and IgG3.   
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Table 1. Characteristics of the IgG Isotype. Compilation of the various characteristics and functions 
of the IgG subclasses. 
 
 
 
 
 
 
CHARACTERISTICS OF IgG 
 
Subclasses: 
 
IgG1, IgG2, IgG3, IgG4 (human) 
IgG1, IgG2a, IgG2b, IgG3 (mouse) 
 
 
Concentration in Sera 
 
IgG1 > IgG2 > IgG3 > IgG4 
 
Complement Activation 
 
IgG3 > IgG1 > IgG2 >> IgG4 (human) 
IgG2a, IgG2b (mouse) 
 
 
FcγR Binding 
 
High affinity receptor -can bind monomeric IgG  
FcγRI: IgG1, IgG3 (weakly binds IgG4) 
  
Low affinity receptors – cannot bind monomeric IgG 
FcγRII: IgG1, IgG2, IgG3 
FcγRIII:IgG1, IgG3 
 
 
Cytokine Influence over Isotype 
Switching 
 
IgE: IL-4 
IgA: Il-5, TGF-β 
IgM: IL-2, IL-4, IL-5 
IgG: IL-2, IL-4, IL-6, IFN-γ 
 
 
 
Th Response 
 
Th1: IgG1, IgG3 (human) 
IgG2a (mouse) 
 
Th2: IgG4 (human) 
IgG1 (mouse) 
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LEISHMANIA 
Parasites of the genus Leishmania are named after W. B. Leishman.  In 
1901 he gave one of the first accounts of the parasites and their association 
with the lesions that are the hallmark symptom of the disease90.  Leishmania 
are single celled, intracellular, protozoan parasites.  They belong to the order 
kinetoplastida and the family trypanosomatidae.  There are various species of 
the parasite, all belonging to the genus Leishmania.  Humans are affected by 
21 of approximately 30 species that infect mammals, causing a broad 
spectrum of disease91.  
 
Life cycle   
Leishmania spp. reside and replicate primarily in host tissue 
macrophages.  There are two developmental stages of the Leishmania life 
cycle (Figure 2), the flagellated promastigote and the nonmotile intracellular 
amastigote.  The promastigote resides in the gut of a phlebotomine sand fly.  
A small pool of blood is formed when a female fly takes a blood meal.  
Infectious promastigotes (metacyclics) are regurgitated into this pool of blood, 
where they enter the human host92.  Phagocytic cells recruited to the site of 
infection rapidly internalize the promastigotes.  Once inside the cell, the 
parasite will find itself in the phagolysosome, where various enzymes reside, 
waiting to kill and digest any invading organisms.  It is in this hostile 
environment that the promastigote transforms into the   
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Figure 2.  The Leishmania Life Cycle. (1)The sandflies inject the infective stage, promastigotes, 
during blood meals. (2)Promastigotes that reach the puncture wound are phagocytized by macrophages 
(3)and transform into amastigotes. (4)Amastigotes multiply in infected cells and affect different 
tissues, depending in part on the Leishmania species. (5-6)This originates the clinical manifestations of 
leishmaniasis.  Sandflies become infected during blood meals on an infected host when they ingest 
macrophages infected with amastigotes. (7)In the sandfly's midgut, the parasites differentiate into 
promastigotes, (8) which multiply and migrate to the proboscis. 
From the Centers for Disease Control, www.cdc.gov 
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nonmotile amastigote.  The parasites not only survive but replicate within the 
acidic phagolysosome.  Replication continues until the host cell is lysed, 
releasing parasites, which in turn infect neighboring cells. 
 
Disease manifestation 
 Approximately 350 million people live in the 88 countries where 
leishmaniasis can be found.  Most of these countries are in the tropics and 
subtropics, however, leishmaniasis is found from the rain forests in Central 
and South America to the deserts in West Asia91.  In humans, Leishmania spp. 
cause a wide spectrum of diseases ranging from confined cutaneous lesions to 
a progressive and sometimes fatal visceral disease.  The degree of disease 
depends upon the species of the parasite and immune competency of the host.  
The various disease manifestations can be classified into three major 
categories: cutaneous (CL), mucocutaneous, and visceral leishmaniasis (VL).   
Cutaneous leishmaniasis begins as small lesions on the skin where an 
infected sand fly has bitten the host.  This form of the disease is often caused 
by L. tropica, L. major, L. amazonensis, and L. amazonensis.  The incubation 
period may range from 1-2 weeks, up to 1-2 months.  Lesions may persist for 
up to a year without treatment, but most will eventually heal93.  This is the 
most prevalent form of the disease with the number of new cases estimated to 
be about 1.5 million per year91.  Ninety percent of these cases occur in 
Afghanistan, Brazil, Peru, Iran, Saudi Arabia, and Syria90.  As recently as June 
28, 2002, the World Health Organization appealed for $1.2 million to help 
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tackle an epidemic that was ongoing in Afghanistan with an estimated 
200,000 cases in Kabul alone90. 
Mucocutaneous leishmaniasis is thought to be the result of metastasis 
from a primary cutaneous lesion to mucosal membranes, since most patients 
have a history of infection with the cutaneous form.  L. braziliensis is often 
responsible for this manifestation.  These lesions progress slowly, but result in 
damage to the mucosal areas in the throat and nose.  Three countries, Bolivia, 
Brazil, and Peru, are responsible for 90% of these cases90.  
Visceral leishmaniasis, also known as kala-azar, results in 
parasitization and subsequent enlargement of the liver and spleen.  L. 
infantum, L. chagsi, and L. donovani are responsible for this form, which is an 
important cause of death in India, Brazil, Bangladesh, and Africa.  The 
incubation period is generally long, 1-3 months, with disease onset 
accompanied by sweating, fever, and weakness.  This is the most serious of 
the disease forms and if left untreated, death may occur93.  There are 
approximately 500,000 new cases of VL per year91. 
 
Diagnosis and treatment 
 Diagnosing leishmaniasis is a difficult task.  Laboratory tests can yield 
negative results even when the person is infected with the organism.  The 
most important and definitive test is the identification of parasites by 
microscopic observation or growth in culture.  Biopsies of the lesion provide 
samples for examination and testing.  Samples are obtained by punch biopsies 
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and needle aspirations of the active lesion.  Giemsa staining slides of the 
biopsied tissue is still the technique most commonly used to detect the 
parasite.  Needle aspirations are used to recover parasites for growth in 
culture.  A needle is placed under the skin, and fluid is aspirated out of the 
lesion.  This fluid is then placed into culture medium and observed for parasite 
growth.  Blood tests to detect antibody against the parasite can be helpful for 
cases involving the visceral form, but these test are frequently not sensitive 
enough to be of use in diagnosing the cutaneous form91. 
Cutaneous lesions will generally heal without treatment, however they 
often leave disfiguring scars.  Other forms of the disease are very difficult to 
treat and often require prolonged treatment with pentavalent antimony drugs 
(Pentostam) or amphotericin B.   
 
Macrophages, Leishmania, and the evasion of intracellular killing 
The uptake of Leishmania by macrophages is a receptor-mediated 
process94.  Due to the obligate intracellular nature of the pathogen, it is 
important that they utilize various receptors to ensure their phagocytosis.  
Complement95;96, fibronectin97, mannose-fucose98, and Fcγ receptors72;99have 
all been shown to be involved in the phagocytosis of these organisms.  Once 
the promastigotes have entered the macrophage, they must contend with the 
harsh environment of the phagolysosome.  The ability of Leishmania spp. to 
not only survive, but replicate in the macrophage phagolysosome is one of the 
most intriguing aspects of Leishmania virulence.   
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Leishmania parasites enter cells by a quiescent mechanism that fails to 
activate innate immune responses, and fails to induce macrophage cytokine 
expression.  Infected macrophages fail to induce TNF-α, IL-12, NO and fail to 
activate NF-κB.  NF-κB activation is critical for inducing co-stimulatory 
molecules on APCs, and for the induction of several genes which encode 
important proinflammatory cytokines100.  Amastigotes101, as well as 
promastigotes102, have previously been observed to not only fail to induce IL-
12 production, but to actively downregulate it.  This proinflammatory 
cytokine is responsible for the production of IFN-γ, which is the hallmark of a 
Th1 immune response.  The downregulation of IL-12 leads to a failure in 
macrophage activation, and ultimately a failure in the intracellular killing of 
Leishmania. 
 
Immune response and deviation 
 The disease spectrum described above is also largely observed in 
murine systems, allowing the mouse to be a reasonable in vivo model.  The 
availability of various strains of inbred mice has allowed extensive 
characterization of the immune response to Leishmania spp.103-105.  These 
studies have found that the type of immune response mounted against the 
parasite determines the outcome of the disease106.  The mouse model is 
especially useful in the study of cutaneous leishmaniasis where disease 
progression can be tracked by lesion size.  The murine model of cutaneous 
leishmaniasis caused by L. major has served as a paradigmatic model in which 
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to study cellular immunity to an intracellular pathogen.  This model has done 
much to help us understand the events leading to T cell biasing and immune 
deviation. 
The outcome of L. major infections in mice has been linked to the type 
of immune response, Th1 or Th2, which is mounted in response to the 
parasite.  CD4+ T lymphocytes from resistant C57BL/6 mice produce high 
levels of IFN-γ and other Th1 cytokines, such as IL-12, while T cells from 
susceptible BALB/c mice produce high levels of IL-4 and IL-10107.  The 
predictability and dramatic differences of this model of disease has led it to 
become the premier model for studying the Th1/Th2 paradigm in vivo.   
In response to L. major, C57BL/6 mice mount a Th1 response, 
characterized by high levels of IFN-γ and IL-12 cytokine production.  This 
appropriate immune response leads to activation of macrophages, which 
promotes healing, parasite clearance, and resolution of infection.  BALB/c 
mice, conversely, mount an inappropriate Th2 response, characterized by IL-
4106;108.  This blocks IFN-γ production and the subsequent macrophage 
activation.  Without macrophage activation, the parasites continue to replicate 
increasing lesion size, and the mice ultimately succumb to the disease.  
Additionally, differences in parasite dissemination have been found in 
resistant and susceptible strains.  Parasite dissemination occurs much more 
rapidly in BALB/c mice, while parasites are contained at the site of infection 
and in draining lymph nodes in resistant C57BL/6 mice109.  This early 
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dissemination in BALB/c mice results in IL-4 producing CD4+ T cells in the 
liver and spleen as early as 2 weeks after infection110. 
Resistance to disease can be conferred upon L. major susceptible 
BALB/c mice by treatment with α-IL-4 antibody111;112, or by knocking out the 
IL-4 gene113;114.  These data established the idea that IL-4 was the driving 
force behind the polarization of the Th2 response in response to L .major, and 
the suppression of Th1 cell development.  The suppression of a Th1 response 
inhibits the production of IFN-γ, which is needed to activate infected 
macrophages for the clearance of parasites.   
It has been shown that a population of CD4+ T cells that recognize the 
Leishmania antigen LACK, a homologue of receptors for activated C kinase, 
was responsible for the early production of IL-4115;116.  However, it was 
determined that this early induction of IL-4 by LACK responsive CD4+ T 
cells was not sufficient to induce susceptibility, because both BALB/c and 
C57BL/6 mice were found to have similar numbers of these cells and thus, a 
production of IL-4 upon infection with L. major106;117.  Additionally, treatment 
of resistant mice with IL-4 or α-IL-12 antibodies at the time of parasite 
infection, leads to a strong Th2 response, but this response is temporary and 
unable to reverse the normal resistance throughout the duration of the 
infection111;118.  Thus, these data indicate that the redirection of the initial Th2 
response is most likely responsible for conferring resistance in L .major 
infected mice. 
  35
The absence of Th1 related cytokines, receptors, transcription factors, 
and co-stimulatory molecules can lead to the susceptibility of resistant mice to 
L .major.  Resistant mice which are deficient in IL-12119, IFN-γ120, T-bet121, or 
CD40-CD40L122;123 interactions, are rendered susceptible to infection with L. 
major, and mount a Th2 immune response, rather than the protective Th1 
response.  Additionally, mice which are deficient in either iNOS124 or TNF125 
are unable to control L. major infections, and develop disease.  Interestingly, 
resistant mice deficient in IFN-γ receptor126 or STAT4127 resulted in an 
increased susceptibility to L .major, but are still able to suppress a Th2 
response.  In the absence of IL-12, other Th1 promoting factors such as IL-18 
and a class-1 cytokine receptor, WSX1, can inhibit a Th2 response and 
influence resistance in the early stages of L. major infection31;128;129.  These 
factors contribute to the redirection of the early Th2 response in resistant 
mice; however the presence of IL-12 and IL-12 receptor signaling is needed to 
maintain a curative Th1 response130. 
The necessity of IL-12 in maintaining resistance was established 
through the use of IL-12 deficient mice.  These normally resistant mice are 
susceptible to infection with L. major, and while intermittently treating with 
IL-12 slows lesion development, they eventually produce progressive lesions.  
Additionally, Th1 cells from healed mice were unable to provide IL-12 
deficient mice with immunity to infection31.  The lesions of healed C57BL/6 
mice, which have achieved clinical, but not sterile cure, reactivate when 
treated with α-IL-12 antibodies131.  Thus the continued presence of IL-12 is 
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necessary to prevent the differentiation of uncommitted cells into Th2 
promoting cells.  The conditions which induce the early onset of an initial Th2 
response are able to reappear upon the depletion of IL-12132. 
Though macrophages are the main target of Leishmania parasites, 
other innate immune cells are important during infection with L. major, 
especially as source of IL-12.  While macrophages are effective at ingesting 
Leishmania parasites, their ability to effectively produce IL-12 is impaired102.  
Dendritic cells (DCs) and epidermal Langerhans cells (LCs) ingest L .major 
parasites and produce IL-12, thus promoting the development of the Th1 
response133;134.  Natural killer cells have also been implicated in the promotion 
of a Th1 response during L .major infections, because of their ability to 
produce the IFN-γ which is needed to optimize the production of IL-12, 
upregulate expression of the IL-12 receptor on T cells, and activate 
macrophages.  It should be noted however, that while NK cells help promote a 
Th1 response, mice deficient in NK cells are still capable of mounting a 
protective Th1 response, and controlling L. major infections135;136. 
There is little doubt that the susceptibility to L .major of BALB/c mice 
is the result of a sustained Th2 response.  However, there is evidence that IL-4 
alone may not be sufficient for susceptibility.  Mice deficient in IL-13 have 
shown that this cytokine is important in mediating susceptibility to L. major, 
and the deletion of both IL-4 and IL-13 has an additive effect on increasing 
disease137.  Additionally, IL-10 is another cytokine capable of suppressing 
Th1 responses, as well as macrophage activation, and CD4+ T cells from L. 
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major infected BALB/c mice have been shown to express high levels of both 
IL-4 and IL-10 mRNA117.  Accordingly, the role of IL-10 in leishmaniasis has 
been demonstrated for both murine72;138;139, and human disease74.   
IL-10 has been identified to be an important mediator of susceptibility 
in both cutaneous and visceral leishmaniasis.  This cytokine has long been 
shown to be elevated in humans suffering with visceral leishmaniasis74.  In a 
recent study, Murray and colleagues demonstrated that macrophage-derived 
IL-10 can increase susceptibility to L. major140.  In addition to 
macrophages72;140, T regulatory cells141 have also been implicated in the 
production of IL-10 during L. major infections.  It is probable that both play a 
role, however, recent evidence supports the role of IL-10 producing Tregs in 
the persistence of parasites after clinical cure, as mice deficient in IL-10 were 
able to achieve sterile cure142.  Mice which obtained a sterile cure from L. 
major infection, whether achieved by IL-10 knockout or treatment with an 
antibody blocking the IL-10 receptor143, were not immune to subsequent 
reinfections, indicating that the maintainance of memory T cells is dependant 
upon parasite persistence.  Tregs were determined to be the source of IL-10 in 
resistant C57BL/6 mice, preventing sterile cure and thus persevering 
immunity.  Thus, macrophages which are the main target of Leishmania 
parasites may be the dominant source of IL-10 during active infection. 
While the classically activated macrophage is necessary for parasite 
clearance, the type II macrophage may be responsible for the production of 
IL-10, and thus Th2 responses, during L. major infections.  It has been 
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previously shown that macrophages, activated in the presence of immune 
complexes, shut off production of IL-1219 and produce high levels of IL-1020.  
These previous observations suggest that immune complexes could adversely 
influence the development of cell mediated immunity to Leishmania spp., by 
inducing this alteration in cytokine production21.  In fact, previous studies 
have shown that the levels of immune complexes are high in patients with 
visceral leishmaniasis144;145.  Immune complexes during Leishmania 
infections would result from the opsonization of parasites with IgG.  
Interestingly, in patients with visceral leishmaniasis, high IgG titers correlate 
with, and are indicative of disease.   
This would also seem to agree with L .major infections in BALB/c 
mice, which develop high antibody titers, with parasites frequently 
metastasizing to the bone marrow, liver, and spleen146.  High antibody titers 
have also been observed in canine leishmaniasis147.  Additionally, the delayed-
type hypersensitivity (DTH) response in BALB/c mice is smaller and more 
transient than in resistant mice148.  Interestingly, 20 years ago it was 
demonstrated that the suppression of DTH responses in BALB/c mice 
required the presence of B cells149.  Therefore, it is possible that antibody 
could play a role in disease by contributing to the formation of immune 
complexes, which in turn induce the production of IL-10 from host 
macrophages. 
Increased levels of IgG, and its subclasses, are present during infection 
with Leishmania spp.147;150-152.  Though the presence of high anti-Leishmania 
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antibody titers and Leishmania immune complexes, as well as a possible role 
for B cells during Leishmania infection have been well documented over the 
last 20 years, no one has offered definitive evidence as to what role B cells 
and/or immunoglobulin plays in mediating the host responses to Leishmania 
infections.  As early as 1982, a role was suggested for humoral factors in 
immunosuppression during visceral leishmaniasis153.  Pearson and colleagues 
repeatedly reported on the presence of immune complexes and their possible 
potential to suppress the immune response during visceral leishmaniasis 
throughout the 1980s145;154-156.  These studies indicated that circulating 
immune complexes were prevalent in patients suffering from visceral 
leishmaniasis, and should be investigated further to determine the role of 
humoral factors in visceral disease and the immunosuppresion of the immune 
response during these infections.  Additionally, a role for polyclonal B cell 
activation was suggested in the formation of immune complexes during 
visceral leishmaniasis by Galvao-Castron et al., in 1984.  These studies noted 
the close association between a marked increase in IgG and IgM levels and 
the presence of immune complexes.   
Murine infections involving B cell depletion, B cell knockouts, and 
IgG deficient mice, seem to support a role for the humoral response in 
mediating the host response to leishmaniasis.  Numerous theories have been 
suggested, but to date, no specific mechanisms involving the host’s humoral 
response to Leishmania spp. have been proven.  In the years leading up to a 
1999 report involving the polarization of T cell responses in the absence of B 
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cells, by Brown and Reiner, almost every report published on the subject of B 
cells and Leishmania infection offered a new theory, but little direct 
eveidence, about their involvement during disease. 
Over 20 years ago, studies were performed in BALB/c mice which had 
been depleted of B cells.  These mice lacked any detectable anti-Leishmania 
antibodies during the course of infection, and were capable of controlling 
lesions.  It was determined that these BALB/c mice displayed a sustained 
DTH response to leishmanial antigen, leading to controlled infection.  It was 
concluded that B cells and antibodies were required for the suppression of the 
DTH response, and subsequent susceptibility in BALB/c mice149.  An 
additional report by Titus and colleagues echoed the similar theme of the role 
of B cells in the development of DTH responses.  In contrast to the previous 
report by Sacks, et al., these studies showed that µMT mice, which lack B 
cells, on the resistant C57BL/6 background, were unable to maintain a 
sustained DTH response following secondary infections, and produced lower 
amounts of IFN-γ than control mice.  The authors conclude that B cells have a 
major role in the development of DTH responses157.  These 2 papers offer 
conflicting theories about the role of B cells during Leishmania infections.  In 
fact, over the past 20 years, there have been several papers reporting on the 
involvement of B cells and/or immunoglobulin during infection with 
Leishmania spp., none of which seem to agree upon the method or 
mechanisms by which B cells and immunoglobulin exert their influence.  
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In 1994, Hoerauf, et al., conducted studies in Xid BALB/c mice during 
the course of L. major infection.  These mice showed slower lesion 
development, 10-30 fold lower parasite burdens, and significant decreases in 
α-L. major antibody levels158.  The authors conclude that B cells contribute to 
the susceptibility in L. major infections by skewing toward a Th2 immune 
response, but offered no mechanism of action.  The authors followed up this 
report in 1995 with similar studies involving Xid BALB/c mice treated with 
IL-7.  Theses studies show that IL-7 results in a total increase in B cells, and a 
100 fold higher parasite load.  The authors conclude that IL-7 enhances 
lymphopoiesis, increasing the number of B cells, and resulting in aggravation 
of L. major disease159.  A similar report by Gessner, et al., in the same year 
also observed the course of leishmaniasis in IL-7 treated mice.  The authors 
treated L. major infected BALB/c mice with IL-7, and observed an increase in 
IL-10, IL-4, and lesion size, as well as accelerated death, and a 40 fold 
increase in parasite burden160.  They concluded that disease enhancement is 
due to the augmentation of B cell lymphopoiesis.  Additional reports the 
following year implicated an increase in B cell number with susceptibility to 
L. major161;162, but again failed to provide a direct mechanism of action.   
Reports by Peters, et al., in 1995, Kima, et al., in 2000, and 
Colmenares et al., in 2002 investigated infections with Leishmania spp. in JH 
mice, which are B cell deficient, on the susceptible BALB/c background.  
These studies illustrated a decrease in disease severity.  Upon treatment with 
Leishmania specific IgG, lesion size increased, suggesting that IgG played a 
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role in increased susceptibility to disease97;163.  These three reports echo each 
other in their conclusions that IgG is important for parasite uptake during 
infection, suggesting that the opsonization of parasites with IgG allows uptake 
through Fc receptors on macrophages, which is the key to susceptibility.  A 
1997 report involving L. major infected BALB/c mice correlated IgG serum 
antibodies with the formation of skin lesions, suggesting that they played a 
role in disease manifestation164. 
In 1999, a report published by Brown and Reiner suggested that 
neither B cells nor antibody play any role influencing the T cells response 
during infections with L. major.  These studies examined µMT mice on both 
the resistant C57BL and the susceptible BALB/c backgrounds.  In these 
studies, there were no differences in the lesion size or development of µMT 
mice, as compared to their appropriate background controls165.  C57BL mice, 
both control and µMT, were able to control infection and mount an 
appropriate Th1 response.  BALB/c mice, control as well as µMT, developed 
progressive lesions and mounted inappropriate Th2 responses upon infection 
with L. major.  Thus, the authors conclude that neither B cells, nor antibody 
mediated effector functions are required for the development of polarized T 
helper cell responses during L. major infections.  The following year another 
paper, published by Smelt, et al., suggested that while B cell deficient mice 
were highly resistant to infection with L. donovani, it was not related to the 
presence, or absence, of IgG.  These studies suggested, rather, that IgG 
protected mice from the neutrophil mediated pathology that occurs during 
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infection166.  These papers reversed the idea of a humoral requirement during 
Leishmania infection, despite almost 20 years of reports indicating a potential 
involvement for B cells, IgG, and/or immune complexes during both murine 
and human leishmaniasis.  In the 5 years following these reports, there has 
been little subsequent investigation into the involvement of humoral factors 
during leishmaniasis.   
 
Summary 
Previous work in our lab has shown that IgG coated immune 
complexes are capable of ligating the FcγR on macrophages.  This leads to the 
abrogation of IL-12, and an increase in the production of IL-10.  We 
hypothesize that IgG coated amastigotes ligate macrophage FcγRs, increasing 
IL-10.  Increased production of IL-10 blocks macrophage activation.  Without 
macrophage activation, Leishmania amastigotes are free to replicate 
unchecked within macrophage phagolysosomes, allowing for the continued 
progression of the disease.  These studies examine this hypothesis and the 
correlation of antibody with the progression of leishmaniasis.   
This work makes the unexpected observations that IgG accesses 
Leishmania within Mφs and that IgG opsonization can lead to disease 
exacerbation.  This points to an unexpected role for IgG in inducing 
susceptibility to intracellular infections. 
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CHAPTER 2:  MATERIALS AND METHODS 
 
Parasites 
  The Friedlin strain of L .major (WHO MHOM/IL/80/Friedlin)167 was 
isolated from an Israeli patient with cutaneous leishmaniasis, and was 
provided to us by David Sacks at the National Institutes of Health, Bethesda, 
MD.  The Josefa isolate of L. amazonensis168 was isolated from a Brazilian 
patient with cutaneous leishmaniasis and was provided to us by Janet Keithly 
at the Wadsworth Center, Albany, NY.  L. chagasi was isolated from a 
Brazilian patient with visceral leishmaniasis, and provided to us by Selma 
Jeronimo at the Universidade Federal Rio Grande do Norte, Natal, Brazil. 
 Promastigotes were cultured in Schneider’s complete medium (SCM), 
which consisted of Schneider’s insect medium (Sigma-Aldrich, St. Louis, 
MO), 20% heat-inactivated (30 min at 56oC) fetal calf serum (HI-FCS, 
Hyclone Laboratories, Logan, UT), 2mM glutamine, 100 µg/mL streptomycin 
and 100 U/mL penicillin G (Mediatech, Herndon, VA).  Lesion-derived L. 
major amastigotes were isolated from infected BALB/c, or C57BL/6 mice as 
described previously168.  Axenic L. chagasi and L. amazonensis amastigotes 
were grown as described previously169.  Briefly, promastigotes were 
resuspended in pH adjusted SCM, and incubated at 33oC, to allow 
transformation to the amastigote stage.  For opsonization of amastigotes with 
IgG, axenically grown amastigotes were incubated for 20 min at 4oC in 
immune serum.  Soluble Leishmania Antigen (SLA) was prepared by freezing 
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late log phase cultures (4-6 days) in liquid nitrogen and immediately thawing 
in a 56oC water bath.  This procedure was performed a total of seven times.  
The culture was then observed by microscopy to confirm the deterioration of 
the parasites.  The parasites were then centrifuged at 2500 rpm for 10 min, and 
the supernatant containing SLA was collected.  A Coomassie Blue assay was 
used to determine the concentration of SLA.   
 
Mouse Strains and Infections 
 These studies were reviewed and approved by the University of 
Maryland Institutional Animal Care and Use Committee.  BALB/c and 
C57BL/6 were purchased from the National Cancer Institute Charles River 
Laboratories, or from Taconic (Germantown, NY).  JH mice170 and FcR γ-
chain knockout171 mice (γ-/-) were purchased from Taconic.   
For infection, mice were injected in the hind footpad with either 2 x 
105 or 2 x 106 amastigotes.  Lesion size was determined by using a caliper to 
measure the thickness of the infected footpad and subtracting the thickness of 
the contralateral uninfected footpad as described previously72.  Parasite 
burdens were determined by a serial dilution of single cell suspensions made 
from excised lesions as described previously72. 
 For immunizations against ovalbumin (OVA), C57BL/6 mice were 
immunized with 25 µg of OVA in 250 µL of Incomplete Freund’s Adjuvant 
(IFA; Difco Laboratories, Livonia, MI), by i.p. injection.  At 2 and 4 wks after 
the initial injection, the mice received a “booster” dose of 25 µg of OVA in 
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250 µL of IFA.  After receiving the final boost, mice were bled to confirm the 
presence of antibodies, and subsequently infected in the right hind footpad. 
  
Primary Cells 
 Murine bone marrow derived macrophages (BMMφ) were established 
as previously described19.  Briefly, bone marrow was flushed from the femurs 
of mice using 5 mL cold PBS, using a 23 gauge needle, and collected by 
centrifugation.  Bone marrow cells were suspended in D-10, which consisted 
of Dulbecco’s Modification of Eagle’s Medium (DMEM, Mediatech) 
supplemented with 10% HI-FCS, 2mM glutamine, 100 µg/mL streptomycin 
and 100 U/mL penicillin G.  Cells were then plated in petri dishes, in D-10 
supplemented with 20% L-929 conditioned media, as a source of macrophage 
colony stimulating factor (m-CSF).  Cells were incubated at 37oC with 5% 
CO2.  For infection of monolayers, macrophages were cultured overnight in 
24-well plates at a density of 2 x 105 cells/well, or on glass coverslips at 1 x 
105.  When required, cells were stimulated with 150 µg/mL low molecular 
weight-hyaluronic acid (LMW-HA, Worthington, Lakewood, NJ) before the 
addition of a 10:1 ratio of L. major amastigotes.   
 Human monocytes were isolated from the blood of normal donors.  
These studies were approved by the IRB of the University of Maryland.  
Blood was collected in heparinized tubes (BD Biosciences, San Jose, CA), 
and then transferred to 50 mL tubes, in 23 mL aliquots.  Total volume was 
brought to 36 mL using PBS.  14 mL of Ficoll-Paque (Amersham 
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Biosciences, Piscataway, NJ) was underlaid by slowly dispensing at the 
bottom of the tube.  Tubes were centrifuged for 20 min at room temperature, 
2500 rpm, and with the brake set to zero.  After the spin, the opaque middle 
layer of PBMNCs, containing the monocytes, was transferred to another 50 
mL tube.  Cells were diluted 1:1 with PBS and centrifuged for 10 min at 4oC 
and 2500 rpm.  The pellet was resuspended in 5 mL PBS, transferred to a 15 
mL tube, and centrifuged at1500 rpm and 4oC for 10 min.  The PBMNCs were 
then counted and either resuspended in a volume appropriate to the specific 
experiment, or plated at 1 x 106 cells/mL in R-20, which consisted of RPMI 
(Mediatech), 20% HI-FCS, 2mM glutamine, 100 µg/mL streptomycin and 100 
U/mL penicillin G, supplemented with 100 µL Hepes per 5 mL of media.  For 
infections, monocytes were given a 10:1 ratio of L. chagasi amastigotes.  In 
some instances, monocytes were stimulated with 10 ng/mL lipopolysaccharide 
(LPS).   
 
Antibodies 
For opsonization and reconstitution experiments, antibodies to L. 
major and L. amazonensis were obtained by bleeding uninfected or infected 
mice.  The blood was allowed to clot, and then centrifuged to recovered sera.  
Purified IgG against L. major was obtained by passing serum from infected 
BALB/c, or C57BL/6 mice through a protein G column on a GradiFrac 
System (Amersham Biosciences).  α-IL-10R monoclonal antibody172 was 
provided by K. Moore (DNAX Research Institute, Palo Alto, CA).  IgG and 
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α-IL-10R treatments were administered by i.p. injections at designated times 
during the experiment.  Serum against L. chagasi was obtained from patients 
with parasitological confirmed cases of visceral leishmaniasis.  Use of human 
sera was reviewed and approved by the Universidad Federal do Rio Grande do 
Norte Ethical Committee (CEPUFRN19/01), by the Brazilian National Ethical 
Committee of Research (CONEP 4572), and the IRB of the University of 
Maryland. 
 
Staining 
To visualize intracellular amastigotes, infected BMMφ, which were 
adhered to glass coverslips, were fixed in methanol at 4oC for 15 min.  
Monolayers were washed with PBS.  Non-specific antibody binding was 
prevented by incubation in blocking buffer (PBS + 10% HI-FCS) for 30 min 
at 4oC.  Monolayers were stained for 45 min at 4oC with antisera from 
Leishmania infected BALB/c mice (1:200).  After washing with PBS, a 1:500 
dilution of fluorescein isothiocyanate (FITC) conjugated goat α-mouse IgG 
antibody (Jackson ImmunoResearch, West Grove, PA) was added to 
monolayers for 45 min at 4oC.  Macrophages were counterstained for 15 min 
with 0.008% Evans Blue (Sigma-Aldrich), or for 1 min with 1% Propidium 
Iodide.   
Intracellular opsonization of axenic L. amazonensis amastigotes was 
determined by infecting monolayers of BMMφ adhered to glass coverslips, 
with a 10:1 ratio axenically grown amastigotes.  After 45 min, monolayers 
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were washed with PBS to remove any unbound amastigotes.  Infected 
monolayers were incubated for 1 hour to allow complete internalization of 
bound amastigotes.  Antisera (5%), from infected BALB/c mice, was added to 
the monolayers for 2 hours, after which time the monolayers were washed to 
remove extracellular IgG.  Monolayers were fixed in methanol at 4oC for 15 
min, and then washed with PBS.  Non-specific antibody binding was 
prevented by incubation in blocking buffer (PBS supplemented with 10% HI-
FCS) for 30 min at 4oC.  The presence of surface IgG on the internalized 
amastigotes was visualized by staining for 45 min at 4oC with a 1:500 dilution 
of FITC conjugated goat α-mouse IgG, specific for total as well as isotype 
specific IgG (Southern Biotechnology, Birmingham, AL).  Macrophages were 
counterstained for 15 min with 0.008% Evans Blue, or for 1 min with 1% 
Propidium Iodide. 
Intracellular opsonization of axenic L. chagsi amastigotes was 
determined by infecting monolayers of primary human Mφ, isolated from 
blood donors then adhered to glass coverslips, with a 10:1 ratio axenically 
grown amastigotes.  After 45 min, monolayers were washed with PBS to 
remove any unbound amastigotes.  Infected monolayers were incubated for 1 
hour to allow complete internalization of bound amastigotes.  Antisera (5%), 
from patients with parasitological confirmed cases of visceral leishmaniasis, 
was added to the monolayers for 2 hours, after which time the monolayers 
were washed to remove extracellular IgG.  Monolayers were fixed in 
methanol at 4oC for 15 min, and then washed with PBS.  Non-specific 
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antibody binding was prevented by incubation in blocking buffer for 30 min at 
4oC.  The presence of surface IgG on the internalized amastigotes was 
visualized by staining for 45 min at 4oC with a 1:500 dilution of FITC 
conjugated mouse α-human IgG, specific for total as well as isotype specific 
IgG (Sigma-Aldrich).  Macrophages were counterstained for 15 min with 
0.008% Evans Blue, or for 1 min with 1% Propidium Iodide. 
Coverslips with adhered, immunostained macrophages were mounted 
on slides using mowiol (Calbiochem, San Diego, CA).  Slides were allowed to 
dry at room temperature for at least 30 min, while being protected from light, 
before visualizing at either 400x or 630x (oil immersion) magnification using 
a Zeiss Axioplan 2 fluorescent imaging research microscope and Zeiss KS300 
imaging software. 
 
Real Time PCR 
JH mice were infected with 2 x 105 L. major amastigotes in the right 
hind footpad.  21 days after infection, mice were given a single i.p. injection 
of 600 µl α-L. major-IgG.  Total RNA was extracted from the footpad lesions 
48 hours after treatment with α-L. major IgG, using the RNAqueous-4PCR kit 
obtained from Ambion (Austin, TX).  IL-10 mRNA levels were detected by 
real-time PCR. Real-time PCR was performed using the ABI PRISM 7700 
Sequence Detection System and SYBR green core PCR reagents (Applied 
Biosystems, Foster City, CA).  The murine IL-10 primer sequences used for 
this analysis were as follows: sense, 5’-CCACAAAGCAGCCTTGCA- 3’ and 
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antisense, 5’ AGTAAGAGCAGGCAGCATAGCA- 3’.  The hypoxanthine 
phosphoribosyltransferase primers used were as follows: sense, 5’-
GTTGGATACAGGCCAGACTTTGTTG-3’ and antisense, 5’-
AGGGTAGGCTGGCCTATAGGCT-3’.   
 
Enzyme Linked Immunosorbent Assay (ELISA) 
Cytokine production from stimulated macrophages was measured by 
ELISA.  Macrophages were seeded in 24-well plates at a density of 2 x 105 
cells/well and incubated overnight at 37oC.  Macrophages were stimulated 
with 150 µg/mL LMW-HA, and axenic, or axenic-opsonized, or lesion 
derived amastigotes at a ratio of 10:1.  Cell supernatants were harvested 24 
hours after infection.  Levels of murine secreted IL-12p40 and IL-10 protein 
concentrations in cell supernatants were determined by sandwich ELISA 
according to protocols provided by BD PharMingen.  Capture and detection 
(biotinylated) antibody pairs (IL-12p40, C15.6 and C17.8; IL-10, JES5-2A5 
and JES5-16E3) and recombinant cytokine protein standards were purchased 
from BD PharMingen.  Streptavidin alkaline phosphatase (AP) and p-
nitrophenyl phosphate (PNPP) substrate were purchased from Southern 
Biotechnology and were used according to the manufacture’s instructions.  
Samples were placed in 96-well flat bottom plates, and measured at 405nm.   
The levels of IL-10 in active footpad lesions were also measured by 
ELISA.  JH mice were infected with 2 x 105 L. major amastigotes in the right 
hind footpad.  21 days after infection, mice were given a single i.p. injection 
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of 600 µl α-L. major-IgG.  After the administration of α-L. major-IgG, IL-10 
protein levels in the infected feet were measured by ELISA.  Lesions were 
homogenized in lysis buffer (15 mM Tris-HCl, 0.5% Triton X-100, 150 mM 
NaCl, 1 mM CaCl2, 1 mM MgCl2) as described previously173.  Samples were 
incubated on ice for 30 min and centrifuged at 850 g for 30 min.  Supernatants 
were then harvested and analyzed by ELISA as described above.   
Cytokine production by lymph node T cells was determined by 
ELISA.  Mice were infected with 2 x 105  L. major amastigotes in the 
presence or absence of 600 µl α-L. major-IgG.  At day 21 after infection, 
lymph nodes were removed, and unfractionated lymph node cells were 
stimulated with 50 µg/mL SLA.  Supernatants were harvested 72 hours later, 
and IFN-γ and IL-4 protein concentrations were measured by ELISA as 
described above.  Capture and detection antibody pairs (IFN-γ, R4-6A2 and 
XMG1.2; IL-4, 11B11 and BVD6-24G2) and recombinant cytokine protein 
standards were purchased from BD PharMingen. 
After infection with L. major, antigen specific IgG isotypes in 
circulating sera were determined by ELISA.  96-well plates were coated 
overnight with 200 ng/well of SLA in coating buffer (15 mM Na2CO2, 34 mM 
NaHCO3, pH = 9.6).  The following day, non-specific binding was blocked by 
incubating wells in blocking buffer for 1 hour at room temperature. Dilutions 
of the sera (1:1000 through 1:500,000) were placed in the wells, and incubated 
at room temperature for 2 hours.  After washing, 100 µL of AP conjugated 
antibodies for total as well as isotype specific IgG (Southern Biotechnology) 
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was added to wells at a 1:2000 dilution, and incubated for 1 hour at room 
temperature.  PNPP was added to wells after washing, and plates were 
incubated in the dark until being read at 405 nm.  The antibody titer was 
determined as the final dilution of sera which had an optical density (OD) 
greater than 0.100. 
 
Flow Cytometry Analysis 
 IL-10 production by human monocytes infected with L. chagasi 
amastigotes was measured by flow cytometry.  Freshly isolated human 
monocytes were infected with a 10:1 ratio of serum opsonized L. chagasi 
amastigotes in the presence of 10 ng/mL LPS. After 15 min, monolayers were 
treated with Golgi Stop (BD Biosciences) for an additional 2 hours.  Surface 
staining to identify monocytes was performed first, by staining with a 1:100 
dilution of a FITC conjugated mouse α-human CD14 antibody (M5E2, BD 
Biosciences) for 30 min at 4oC.  Monocytes were washed in PBS, and then 
fixed and permeablized using the CytoFix/CytoPerm solution (BD 
Biosciences) for 20 min at 4oC.  Intracellular IL-10 was detected using a 1: 
100 dilution of a phycoerythrin (PE) conjugated rat α–human IL-10 
monoclonal antibody (JES3-19F1, BD Biosciences) for 30 min at 4oC.  
IgG on the surface of lesion derived amastigotes was measured by 
flow cytometry. Surface IgG from lesion derived L. major amastigotes was 
carried out immediately after amastigotes were isolated from the footpad 
lesions of BALB/c or C57BL/6 mice.  Amastigotes were incubated in a 1:500 
  54
dilution of FITC conjugated goat α-mouse isotype specific IgG for 45 min at 
4oC.  Amastigotes were washed with PBS, and fixed in fresh 4% 
paraformaldehyde. 
Intracellular opsonization of axenic L. amazonensis amastigotes was 
determined by flow cytometry.  Monolayers of BMMφ, seeded at a density of 
in 1 x 106 BMMφ/well in 6-well plates, were infected with a 10:1 ratio 
axenically grown amastigotes.  After 45 min, monolayers were washed with 
PBS to remove any unbound amastigotes.  Infected monolayers were 
incubated for 1 hour to allow complete internalization of bound amastigotes.  
Antisera (5%), from infected BALB/c mice, was added to the monolayers for 
2 hours, after which time the monolayers were washed to remove extracellular 
IgG.  Macrophages were taken up by incubating in Cell Stripper (Mediatech) 
at 37oC for 10 min, washed in PBS, and lysed using a series of syringes, as 
described in the amastigote isolation procedure.  Isolated amastigotes were 
fixed in fresh 4% paraformaldehyde at 4oC for 15 min.  The presence of 
surface IgG was visualized by staining for 45 min at 4oC with a 1:500 dilution 
of FITC conjugated goat α-mouse IgG, specific for total as well as isotype 
specific IgG (Southern Biotech, Birmingham, AL). 
Following fixation, cells were washed in PBS and analyzed by flow 
cytometry using a Becton Dickinson FACSCalibur benchtop flow cytometer 
and CellQuest software. 
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CHAPTER 3:  A ROLE FOR IgG IMMUNE COMPLEXES 
DURING INFECTION WITH LEISHMANIA 
 
Opsonization and Association with Macrophages 
Leishmania amastigotes are known to have host IgG on their 
surfaces174;175.  It was thought that this provided opsonization of the 
organisms, facilitating amastigote entry into macrophages.  Although previous 
publications have demonstrated the presence of IgG on amastigote surfaces72 
(Figure 3), no experiments have been performed to determine how the 
amastigotes and IgG come into contact.  It was assumed that as the parasites 
replicate, bursting host macrophages, the amastigotes were released into the 
extracellular milieu, and there they encountered host IgG.  We hypothesized 
that IgG can access amastigotes intracellulary. 
The neonatal receptor is instrumental in the regulation of IgG serum 
levels, salvaging IgG from degradation within macrophage phagolysosomes.  
IgG binds to the receptor in the acidic phagolysosome environment.  Upon 
receptor recycling to the cell surface, the neutral pH causes the IgG to be 
released from the receptor, thus maintaining IgG levels176-178.  It is possible 
that amastigotes and IgG could come into contact during this process, and 
result in amastigotes which had been opsonized intracellularly.  An 
experiment was performed to determine whether IgG could bind to axenic L.  
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Figure 3. Lesion Derived Amastigotes Have Host IgG on Their Surfaces. Amastigotes 
isolated from active BALB/c lesions were added to macrophage monolayers. After a 45 min 
incubation, unbound parasites were washed away, and the amastigote containing macrophages 
were fixed. A FITC conjugated goat α-mouse IgG antibody (1:500) allowed the visualization 
of host (murine) IgG on the surface of amastigotes (green). Macrophage nuclei (red) were 
counterstained with propidium iodide (1:1000). 
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amazonensis amastigotes after their uptake into macrophages, and opsonize 
them intracellularly.  Axenic amastigotes were grown in cell free culture, and 
thus have no IgG on their surface.   
Monolayers of macrophages were infected 10:1 with axenic L. 
amazonensis amastigotes.  After an initial incubation, unbound amastigotes 
were washed away, and 5% sera from either normal, naïve BALB/c mice, or 
chronically infected mice, was added to the media and allowed to incubate for 
2 hours.  After staining with a FITC-conjugated anti-IgG antibody, it was 
evident by both fluorescent microscopy (Figure 4 A,B) and flow cytometry 
(Figure 4 C) that immune serum was able to access the amastigotes, which 
were presumably within the macrophage, and bind to its surface.  These data 
suggest that antigen specific IgG may be able to enter macrophages and 
opsonize amastigotes intracellularly. 
To determine whether host IgG was an opsonin that was necessary for 
amastigotes to gain entry into host cells, we infected BALB/c macrophage 
monolayers with IgG-free axenic, axenic amastigotes opsonized with IgG, and 
with lesion derived amastigotes.  Axenic opsonized amastigotes were made by 
incubating axenic amastigotes in 5% sera to allow them to become opsonized 
with IgG.  We also used lesion derived amastigotes, which were isolated from 
active lesions in mice, and are thus coated with murine IgG72.  Over a 120 min 
time course, the L. amazonensis axenic, axenic-opsonized, and lesion 
 
 
  58
 
 
Figure 4. The Intracellular Opsonization of L. amazonensis Amastigotes. Macrophages were 
infected with axenic L. amazonensis amastigotes, and then incubated in either normal or immune sera.  
After the incubation with sera, monolayers were washed, and amastigotes were stained for the presence 
of surface IgG (green). Macrophages were counterstained with Evans Blue (red). Immune sera (B), but 
not normal sera (A) was able to opsonize amastigotes. Flow cytometry on the amastigotes (C) was 
performed to quantify surface staining. These findings suggest that only immune sera was able to 
opsonize amastigotes intracellularly. 
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derived amastigotes displayed a similar ability to associate with macrophages 
(Figure 5).  Thus, the presence of IgG does not increase the ability of 
amastigotes to associate with macrophages.  
A similar study was performed using macrophages from γ-/- mice.  
These mice are deficient in the FcR γ chain.  The association of the Fc binding 
chain (α) and the signaling chain (γ) is necessary for the expression of FcRs.  
Thus, knocking out the γ chain results in the reduced activity of these 
receptors.  The association of amastigotes with γ-/- macrophages was 
compared to macrophages from BALB/c mice.  Lesion derived amastigotes, 
which are coated in IgG, associated similarly to both BALB/c macrophages 
and macrophages that are deficient in the FcR γ chain (Figure 6).  Various 
multiplicities of infection (MOIs) were used, and parasite association with 
both types of macrophages was similar, regardless of parasite number.  
Together, these figures show that neither IgG on the surface of amastigotes, 
nor the FcγR on the surface of macrophages affects amastigote association 
with macrophages. 
 
Mice Lacking IgG Are More Resistant to Leishmania Infection 
To determine a role for IgG antibodies in the host immune response to 
Leishmania spp., we infected normal BALB/c mice with L. amazonensis 
(Figure 7) parasites and compared the course of infection to that which 
occurred in the JH strain of mice on the BALB/c background.  JH mice have a  
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Figure 5. The Role of IgG in Amastigote Association. Lesion derived (closed 
circles), Axenic (open circles), and axenic-IgG (closed triangles) L. amazonensis 
amastigotes (10:1) were added to Mφ monolayers for 15, 30, 60, and 120 minutes. 
Monolayers were then washed, fixed and stained to allow visualization of bound 
amastigotes. Error bars represent the standard error of the mean of 3 separate 
experiments.
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Figure 6. FcγRs in Amastigote Association. Association of lesion derived L. 
amazonensis amastigotes with macrophages from γ-/- (open circles) and BALB/c 
(closed cirlces) mice. Parasites were added to monolayers at MOIs of 2.5:1, 5:1, 
10:1, and 20:1, for 45 min. Monolayers were then washed, fixed and stained to 
allow visualization of bound amastigotes. Error bars represent the standard error of 
the mean of 3 separate experiments. 
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Figure 7.  L. amazonensis progression in JH vs. BALB/c mice.  Footpad swelling in JH (closed 
circles, n=4) and BALB/c mice (open circles, n=4) was compared following infection in the 
right hind footpad with 2x106 amastigotes. Groups begin to differ after day 21, with JH 
developing significantly smaller lesions than their wild type counterparts. Parasite burdens 
(inset) mirror the findings of the footpad measurements. Error bars represent the standard 
deviation of the mean of 4 determinants. 
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targeted deletion of the immunoglobulin heavy chain J locus and, therefore, 
make no antibody.  Normal BALB/c mice are susceptible to Leishmania 
infections179 and developed large lesions (Fig.7 open circles).  As expected, JH 
mice develop smaller lesions (Fig.7 closed circles) with fewer parasites within 
the lesion (Fig.7 closed bar, inset).  These data suggest that the absence of 
antibody in JH mice leads to increased resistance to L. amazonensis.   
 
Addition of IgG Exacerbates Disease in JH Mice 
A similar experiment was performed using JH mice infected with L. 
major.  JH mice were relatively resistant to disease, developing modest lesions 
(Figure 8, filled triangles), which contained several orders of magnitude fewer 
parasites (Fig.8, inset) than the wild-type BALB/c mice.  The passive 
administration of polyclonal α- L. major antiserum to wild-type BALB/c mice 
had essentially no effect on lesion progression (Fig. 8, open circles).  These 
mice developed lesions with the same size and kinetics as mice that received 
no antisera.  Furthermore, the two groups of BALB/c mice had similar 
numbers of parasites within their lesions at the conclusion of the observation 
period 35 days post infection (Fig.8, inset).  In 3 separate experiments, using a 
minimum of 4 mice per experimental group, the mean lesion size of infected 
JH mice was 1.22 +/- 0.31 mm at 35 days post-infection, whereas infected  
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Figure 8.  Serum Reconstitution of JH Mice.  Lesion size of JH mice (filled triangles) and 
BALB/c mice (filled circles) was compared to JH mice (open triangles) and BALB/c mice 
(open circles) given 200 µl antisera to L. major on days 1, 7 and 14.  Parasite burdens (inset) 
in BALB/c and JH mice that were infected with (striped bars) or without (solid bars) α-L. 
major antisera were determined on Day 35, by limiting dilution assays.  Error bars represent 
the standard error of the mean of 3 separate experiments, with a minimum of 4 mice per 
group. 
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BALB/c mice developed lesions that were 5.01 +/- 0.43 mm.  The passive 
administration of immune serum to JH mice reversed this resistant phenotype 
and actually exacerbated disease, restoring lesion size to that observed in 
wild-type BALB/c mice (Fig.8, open triangles).  The number of parasites in 
these lesions was comparable to that observed in wild-type BALB/c mice 
(Fig.8, inset).   
A similar study was performed on JH mice, except that α-L. major 
antiserum was administered to the mice after the infection had progressed for 
3 weeks.  This was done to determine the speed with which antibody to L. 
major could exacerbate infections (Figure 9).  In these studies, two groups of 
JH mice were infected with L. major for 3 weeks.  One of the groups was then 
given a single 200 µL i.p. injection of α-L. major antiserum.  Within 1 week 
of antiserum administration, footpad lesions in this group were already 
significantly larger than the controls.  Three weeks after the injection of 
antiserum, the lesions had progressed to a point where their size (Fig. 9, open 
circles), and the number of parasites within them (Fig. 9, inset) was 
comparable to susceptible BALB/c mice.  Similar studies were performed 
using IgG that was affinity purified from the immune serum used in Figure 9.  
A single i.p. injection of 600 µg of purified α-L. major IgG into mice at 3 
weeks post-infection caused a similar increase in lesion formation with 
kinetics that were similar to unfractionated immune serum (Figure 10). 
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Figure 9.  Serum Reconstitution of JH Mice 3 Weeks Post-Infection.  Lesion size of JH 
mice (filled circles) were compared to those of JH mice given 200 µl  α-L. major antiserum on 
day 21 post-infection (open circles). Parasite burdens (inset) were determined at 42 days post-
infection by limiting dilution assays, as described. Error bars represent the standard deviation 
of the mean of 4 determinations.  This experiment is representative of three. 
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Figure 10. Reconstitution of JH mice 3 Weeks After Infection with Either α-L. major 
Antiserum or Purified α-L. major IgG. Lesion size of JH mice (closed circles) was 
compared to those of JH mice given 200 µl α-L. major antiserum (open circles) or 600 µl α-
L. major IgG (closed triangles) on day 21 after infection. Error bars represent the standard 
deviation of the mean of 4 determinations. 
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IL-10 Production During Leishmania Infection 
Cytokine production from lymph node T cells was analyzed in vitro, 
following the infection of JH mice with L. major in the presence or absence of 
antibody, in vivo.  The administration of α-L. major IgG resulted in a  
significant increase in the production of IL-4 by lymph node T cells which 
were restimulated in vitro (Figure 11 A), but little to no decrease in the 
production of IFN-γ levels by these cells.  Thus, the presence of antibody to L. 
major correlates with an increase in IL-4 production by parasite-specific T 
cells. 
The alteration in the production of these T cell cytokines did not 
appear to be substantial enough to account for the large differences in lesion 
formation observed in these mice.  Consequently we examined a possible role 
for IL-10.  Our lab72 and others138;139 have previously shown that mice lacking 
IL-10 were relatively resistant to leishmaniasis.  We examined the production 
of IL-10 in the lesions of mice infected with Leishmania.  IL-10 mRNA and 
protein were measured in infected feet 2 and 4 days, respectively, after the 
administration of α-L. major IgG.  JH mice given a single dose of purified α-
L. major IgG i.p. produced approximately twice as much IL-10 protein and 
mRNA in their lesions, relative to parallel groups of mice infected at the same 
time, which did not receive IgG (Figure 11 B).   
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Figure 11 A.  Cytokine Production in Mice Administered α-L. major Antiserum.  Cytokine 
production by lymph node T cells from infected JH mice (open bar) was compared to JH mice 
administered 200 µl α-L. major antiserum on days 1, 7, and 14 post-infection (solid bar).  Lymph 
nodes were removed on day 21 and stimulated with SLA.  Supernatants were harvested 72 hr later 
and assayed for IFN-γ and IL-4 by ELISA. 
 
Figure 11 B.  IL-10 Production in Lesions of JH Mice.  IL-10 protein (left) and mRNA (right) 
were determined in two groups of JH mice infected with 2x105 L. major amastigotes.  On day 21 
of infection, one group was administered 600 µg purified α-L. major IgG i.p.   IL-10 protein levels 
in the lesions of three infected mice were measured by ELISA, 4 days following the 
administration of α-L. major IgG (left axis).   RNA was isolated from footpad lesions on day 2 
post-IgG administration, and real time PCR was performed to determine relative IL-10 mRNA 
(right axis).   Levels represent the average from three infected mice, and mRNA was normalized to 
HPRT levels in a single infected foot. 
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To confirm a role for IL-10 in lesion progression, JH mice were 
infected with L. major and administered purified α-L. major IgG along with a 
monoclonal antibody to the IL-10 receptor.   Infected JH mice  
developed modest lesions (Figure 12, filled circles; Figure 13 A), whereas 
those administered α-L. major IgG developed large lesions (Fig.12, open 
circles; Figure 13 B) with high numbers of parasites (Fig.12, inset).  The 
administration of a monoclonal antibody to the IL-10 receptor completely 
prevented the exacerbation of disease caused by α-L. major IgG (Fig. 12, grey 
triangles; Figure 13 C).  In fact, the footpad lesions in mice treated with α-L. 
major IgG plus α-IL-10R, essentially resembled an uninfected footpad.   
To further show the relationship between macrophage, IgG, and IL-10, 
axenic amastigotes were opsonized and examined for their ability to induce 
the production of IL-10 from macrophages.  Axenic L. amazonensis 
amastigotes were opsonized with sera from normal and infected BALB/c or JH 
mice, and added to monolayers of macrophages.  JH mice are unable to 
produce IgG, and therefore will not be able to ligate FcγRs on macrophages.  
This experiment tests the hypothesis of IL-10 induction being the result of IgG 
immune complexes ligating the FcγRs on macrophages.  Without the ligation 
of FcγRs, the cytokine production should not be altered, and the production of 
IL-10 should not be induced.   
Amastigotes opsonized with normal sera from either strain of mouse 
were unable to induce the production of IL-10 (Figure 14, closed bars).  When 
axenic amastigotes were opsonized with sera from BALB/c mice, they were  
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Figure 12.  IgG Reconstitution of JH Mice and the Effect of α-IL-10R mAb. Three parallel 
groups of JH mice were infected with 2x105 L. major amastigotes.  One group (open circles) 
was administered 600 µg purified α-L. major IgG i.p. on days 1, 8, and 15.  Another group 
(grey triangles) was given the same dose of  α-L. major IgG, along with α-IL-10R on days 0 
[1mg], 7 [200 µg],  and 14 [200 µg]. The third group (filled circles) received no treatment.   
Lesion size was measured at semi-weekly intervals.  Parasite burdens (inset) were determined 
by limiting dilution. Error bars represent the standard deviation of the mean of 4 
determinations. This experiment is representative of 3.  
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Figure 13.  IgG Reconstitution of JH Mice and the Effect of α-IL-10R mAb. Pictures of 
footpads from Fig.12. Footpads of JH mice were infected with 2x105 L. major amastigotes.  
One group (B) was administered 600 µg purified α-L. major IgG i.p. on days 1, 8, and 15.  
Another group (C) was given the same dose of  α-L. major IgG, along with α-IL-10R on days 
0 [1mg], 7 [200 µg],  and 14 [200 µg]. A third group (A) received no treatment after infection. 
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Figure 14.  In vitro Cytokine Production. Axenic L. amazonensis amastigotes (AA) 
were opsonized with sera from either normal (closed bars) or immune (open bars) 
BALB/c or JH mice.  Amastigotes were added to macrophages in the presence of 
inflammatory low molecular weight hyaluronic acid (LMW-HA) at a ratio of 10:1.  
Supernatants were harvested 24 hrs later and IL-10 production measured by ELISA. This 
experiment is representative of 3. 
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able to induce macrophages to produce a robust IL-10 response (Fig.14, open 
bar).  Immune sera from JH mice (Fig.14, open bar) was unable to induce the 
production of IL-10.  The failure of these amastigotes to induce IL-10, 
demonstrates the necessity for IgG containing immune complexes in this 
process. 
 
Immunization of C57BL/6 Mice Leads to Increased Disease 
To determine whether irrelevant immune complexes, which are 
unrelated to the ongoing L. major infection, could have an effect on lesion 
progression, we immunized the genetically resistant C57BL/6 mice with 
ovalbumin (OVA) in incomplete Freunds adjuvant (IFA).  Mice were boosted 
2 weeks later, and 4 weeks after the initial immunization.  These mice 
developed high titers of IgG antibody to OVA.  They were then infected with 
L. major suspended in a solution of PBS containing 50 µg/mL OVA.  
Immunized mice developed larger lesions (Figure 15, open circles) with more 
parasites (Fig. 15, inset), compared to control mice receiving IFA alone and 
the same L. major infection (Fig. 15, closed circles).    
 
IgG antibodies in human visceral leishmaniasis 
In vitro infection studies were performed to measure IL-10 production 
from human monocytes infected with L. chagasi amastigotes.  For these 
studies IgG-free axenically grown L. chagasi amastigotes were used to infect 
normal human monocytes.  Axenic amastigotes induced little to no detectible  
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Figure 15.  The Immunization of C57BL/6 Mice with OVA.  Lesion development in 
OVA-immunized mice (open circles) was compared to control mice given IFA alone 
(filled circles).  Immunized mice were given 25µg OVA in 500µL of IFA, and boosted 2 
weeks later.  Both groups of mice were infected with L. major resuspended in PBS 
containing 50 µg/mL OVA.  Parasite burdens (inset) were determined on Day 34.  Error 
bars represent the standard deviation of the mean of 4 determinants. This experiment is 
representative of 3. 
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IL-10 production from human monocytes (Figure 16, red line).  However, 
incubating these organisms in serum from a patient with visceral leishmaniasis 
induced the production of high levels of IL-10 from monocytes (Fig. 16, blue 
line).    Parallel groups of axenic amastigotes incubated in normal serum from 
uninfected volunteers failed to induce IL-10 production from monocytes (Fig. 
16, green line).  Thus, serum from infected patients opsonizes amastigotes to 
induce the production of IL-10 from infected monocytes. 
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Figure 16.  Flow Cytometry to Detect Intracellular IL-10.  Human monocytes were 
infected with a 10:1 ratio of axenic amastigotes of L. chagasi.  Prior to infection some 
amastigotes were incubated at 4C for 15 minutes in 5% serum from either an uninfected  
volunteer (naïve serum) or from a patient with visceral leishmaniasis (VL serum).  Monocytes 
were incubated in Golgi-stop for 2 hrs, fixed, and permeabilized and stained for intracellular 
IL-10 expression.  Cells were gated on CD14 expression. This experiment is representative of 
3. 
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Discussion 
In the present studies, we examine the host response during the 
development of leishmaniasis, using murine and human models.  Leishmania 
amastigotes have been shown to have host IgG on their surfaces174;175, and it 
has been accepted for some time that IgG played a role in leishmaniasis.  It 
was assumed that the role IgG fulfilled was as an opsonin, allowing the 
parasite more efficient entry in to the macrophage97.  We examined how IgG 
and amastigotes came into contact with each other, and whether amastigote 
opsonization was essential for entry into neighboring cells.   
IgG can enter macrophages, where it is saved from degradation by the 
neonatal receptor, also known as the IgG protective receptor176-178.  A study 
involving the intracellular bacterium, Listeria monocytogenes, found that once 
inside the macrophage, antibody molecules could traffic within the endosomal 
compartments of the cell and encounter Listeria containing vacuoles180.  Since 
Leishmania spp. also reside inside macrophages, we examined the possibility 
of intracellular amastigote opsonization as they reside within the cell.  We 
determined that immune sera from chronically infected BALB/c mice, but not 
normal sera from naïve mice, could enter macrophages, and coat amastigotes 
intracellularly.  This suggests that IgG must be specific to the amastigote for 
opsonization to occur, and this opsonization can occur inside, as well as 
outside, host macrophages.  We show that L. amazonensis amastigotes gain 
entry into host macrophages regardless of opsonization.  Axenic amastigotes 
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were able to invade wild type (Fig. 5) macrophages with kinetics similar to 
IgG opsonized, and lesion derived amastigotes.  Also, lesion derived 
amastigotes were able to bind with similar kinetics to both wildtype and and 
FcR γ-/- macrophages (Fig. 6).  This ruled out the necessity of both IgG 
opsonization, and the binding to the FcγR, for the entry of amastigotes into 
cells.  Thus, IgG must be serving some other role in the pathogenesis of 
leishmaniasis.   
Interestingly, Peters, et al., demonstrated in 1995 that B cell deficient 
mice injected with specific IgG, showed surface bound IgG upon isolation of 
lesion amastigotes.  However, amastigotes isolated from B cell deficient mice 
injected with naïve sera were IgG negative97.  The authors suggested that 
specific antibodies injected into the tail vein had access to lesion formation in 
the footpad. 
The investigation into B cells, IgG, and leishmaniasis has been well 
documented97;149;157;158;161;163;165;166;181;182.  Most of these papers agree that B 
cells and IgG play a role in leishmaniasis, but there is no agreement as to what 
extent, and how they influence the course of disease.  While several groups 
acknowledge a direct role for IgG in leishmaniasis97;163;166;182, no one has 
shown a definitive mechanism by which B cells and IgG exert their influence. 
We reexamined the role of IgG in host defense to Leishmania spp. 
using JH mice.  The JH strain of BALB/c mice lacks IgG because they have a 
targeted deletion in the immunoglobulin heavy chain (J) locus.  JH mice were 
more resistant to infections with L. major than were normal BALB/c mice.  
  80
When these mice were reconstituted with sera from chronically infected 
BALB/c mice, they exhibited larger lesions, with higher numbers of parasites 
residing in those lesions.  These data show that the presence of antibody to L. 
major did not protect BALB/c mice, and in the case of the IgG deficient JH 
mice, the presence of IgG actually exacerbated disease.  This provides 
evidence that intracellular organisms can exploit IgG, normally considered to 
be a protective component of our immune system, and use it to their benefit, 
thus causing harm to the host. 
In patients with visceral leishmaniasis, high IgG titers correlate with 
disease.  IL-10 production in both cutaneous and visceral leishmaniasis has 
been previously reported72;138;139.  A role for IL-10 has been demonstrated for 
both murine72;138;139, and human disease74.  We examined the production of 
IL-10 during murine L. major infections, and showed the effect of IL-10 
receptor (IL-10R) blockade on disease progression.  We showed that by 
blocking IL-10, using a monoclonal antibody against the IL-10 receptor, we 
were able to reverse the IgG mediated increase in disease susceptibility.  This 
provides direct evidence for the requirement of IgG and IL-10 in the 
susceptibility of mice to L. major.  Providing further evidence for the role of 
IL-10, we showed that IL-10 protein and mRNA levels were higher in the 
lesions of antibody treated mice. 
The cells responsible for the production of IL-10 during infection with 
Leishmania spp. have not been definitively identified.  Previously it was 
determined that regulatory T cells play a role in sustaining murine cutaneous 
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leishmaniasis183.  Tregs can produce IL-10, and these cells may be a source of 
IL-10 during disease progression.  We showed that the IL-10 production 
during L. major infections had a detrimental effect on the host by exacerbating 
the infection.  Previous studies20;23 have shown that macrophages produce IL-
10 upon the ligation of their FcγRs by immune complexes.  We examined 
whether this phenomenon could apply to L. major infections, with L. major –
α-L. major IgG serving as the immune complex responsible for FcγR ligation.  
Further showing that the production of IL-10 is from macrophages, we 
isolated peripheral blood mononuclear cells (PBMNCs) from the blood of 
normal human donors, and infected them with opsonized L. chagasi.  L. 
chagasi amastigotes opsonized with sera from infected patients were able to 
induce the production of IL-10 from monocytes.  These data show that 
infected macrophages can also produce IL-10 in response to FcγR ligation by 
L. major –α-L. major IgG, and L. chagsi –α-L. chagasi immune complexes.  
We conclude that IgG can cause a novel form of immune enhancement, due to 
its ability to induce IL-10 production from macrophages. 
The IL-10 produced by macrophages has both a direct and an indirect 
effect on the progression of leishmaniasis.  IL-10 is a potent inhibitor of 
macrophage activation, providing a direct way in which immune complexes 
can prevent the elimination of parasites, even in the presence of an ongoing 
immune response.  Immune complexes also have an indirect effect by 
influencing APC cytokine production, to bias T cell responses (Fig. 11 A).  
Our data show that irrelevant immune complexes (Fig. 15), as well as 
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amastigote-IgG immune complexes, were sufficient to increase disease.  This 
illustrates that this phenomenon is not parasite specific, but rather due to the 
induction of IL-10 by type II activated macrophages.  In lesions, macrophages 
and dendritic cells19;134 are in close association with T cells.  This means that 
they are in a prime position to influence T cell cytokine production, and both 
macrophages19 and dendritic cells184 shut off their production of IL-12 in 
response to immune complexes.  In fact, when T cells from infected lymph 
nodes were restimulated in vitro, we showed that these cells produced high 
levels of the Th2 cytokine, IL-4.  
  Interestingly, 20 years ago it was demonstrated that the susceptibility 
of BALB/c mice required the presence of B cells149.  Also a more recent study 
has demonstrated that IgG could increase susceptibility to L. amazonensis 
infections in mice163, but did not identify the mechanism by which this 
increased susceptibility occurred.  We show a role for IgG immune complexes 
in leishmaniasis, and conclude that IgG not only fails to provide protection 
against infection with Leishmania spp., but it can actually contribute to the 
disease progression. We demonstrate that the mechanism of this exacerbation 
is due to the induction of the anti-inflammatory cytokine, IL-10, rather than 
the production of the inflammatory and macrophage activating cytokine, IL-
12.   
Previous studies have identified immune complexes to be present in 
patients with visceral leishmaniasis144;145.  High antibody titers have been 
observed in canine, as well as in human, visceral leishmaniasis147;151;185.  The 
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observations made in the murine model of leishmaniasis were confirmed in in 
vitro studies involving human cells and the causative agent in human visceral 
leishmaniasis, L. chagasi.  Infection of human monocytes with axenic L. 
chagasi amastigotes opsonized with antisera from infected patients, resulted in 
the production of IL-10.  This data confirmed our hypothesis of IgG immune 
complexes inducing the production of IL-10 by ligating FcγRs on 
macrophages.  This data also provides a mechanism by which these two 
factors contribute to disease progression. 
In many ways the infection of BALB/c mice with L. major may be a 
better model for human visceral leishmaniasis than for cutaneous 
leishmaniasis.  BALB/c mice are susceptible to infection with L. major, and 
develop high antibody titers.  During infection, the parasites frequently 
metastasize to the bone marrow, liver, and spleen146, and similar to human 
visceral leishmaniasis, BALB/c mice will typically succumb to infection.  
Thus, it is possible that some of the observations made in the BALB/c model 
of infection with L. major can be extended to human visceral leishmaniasis. 
These data suggest a novel form of antibody-dependent immune 
enhancement, where the immune complexes influence cytokine production, 
and prevent the eradication of intracellular pathogens.  These observations 
may also provide a general mechanism to help explain antibody dependent 
immune enhancement (ADE).   The phenomenon of ADE has been observed 
in Dengue hemorrhagic fever186, where the presence of antibody causes a 
marked increase in viremia and viral pathogenesis.  IL-10 gene homologs 
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have also been found in the genomes of several viruses.  Considering the 
inhibitory effects of IL-10 on the inflammatory response, the capture of an IL-
10 gene by a virus could be extremely beneficial to viral survival.  An 
increased rate of mortality in meningococcal disease is also associated with a 
genetic predisposition of a higher level of IL-10 expression57.  Intracellular 
bacteria have been shown to use IL-10 as a mechanism to establish disease, as 
studies have associated the production of IL-10 from macrophages with the 
progression of lepromatous leprosy187.   The present studies would suggest 
that antibody-mediated immune enhancement, resulting in IL-10 production 
from macrophages, should be considered as a potential risk for some 
vaccination protocols. 
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CHAPTER 4: IgG DIFFERENCES BETWEEN SUSCEPTIBLE 
AND RESISTANT MICE 
 
Addition of BALB/c Antisera, but not C57BL/6, Influences the Progression of Disease 
Leishmania major infections have been extensively studied in mice, 
and are an excellent model for the Th1/Th2 paradigm.  It has been shown that 
the type of immune response mounted results in either resolution or 
susceptibility to disease103-106;108.  L. major infections in C57BL/6 mice result 
in a Th1 response, leading to the resolution of the infection.  The same 
infection in BALB/c mice results in a Th2 response, leading to disease 
susceptibility.  BALB/c mice are known to be exceptionally susceptible, 
regardless of infective dosage, displaying high antibody titers, parasite 
metastasis146;188, and eventually, loss of infected extremities188.   
We demonstrate that JH mice, which lack IgG, are more resistant to 
infection with Leishmania spp. than the control BALB/c mice (Figs. 7, 8).  
However, reconstitution with α-L. major sera from BALB/c mice rendered JH 
mice more susceptible to infection with L. major (Fig. 8).  The goal of these 
studies was to determine whether L. major antiserum from C57BL/6 mice was 
similar to, and could exert the same effects as, BALB/c antisera.  An 
experiment was performed to determine the effects of the reconstitution of JH 
mice with α-L. major antisera from C57BL/6 mice.  The administration of 
C57BL/6 derived α-L. major antisera had no effect on the progression of 
disease in JH mice (Figure 17, open triangles).  These mice developed lesions 
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similar to JH mice which received no antisera.  These two groups also had 
similar numbers of parasites within their lesions at the conclusion of the 
experiment on day 35 (Fig. 17, inset).  Both BALB/c (Fig. 17, closed circles) 
and JH mice administered BALB/c derived antisera (Fig.17, closed triangles) 
are susceptible to infection with L. major, and develop large lesions with high 
numbers of parasites within their lesions (Fig. 17, inset).  These data suggest 
that while the passive administration of immune serum from BALB/c mice 
can exacerbate disease, the antiserum obtained from C57BL/6 mice is unable 
to influence the progression of L. major infections in JH mice. 
We previously showed a role for IgG in the progression of L. major 
infections189.  The presence of IgG was linked to the formation of immune 
complexes, which ligate FcγRs on macrophages and induce the production of 
IL-10 from these macrophages.  These data, along with the differences 
discovered between the pathogenicity of BALB/c antisera in JH mice, with 
respect to the inability of C57BL/6 antisera to affect disease, pose interesting 
questions regarding how these IgG differences relate to disease progression.  
These data suggest that IgG could influence leishmaniasis in several ways.  
The presence of immune complexes influences cytokine production by 
macrophages, resulting in a Th2 environment, which leads to the production 
of other Th2 cytokines, including those that stimulate a robust IgG response 
and isotype switching.  The resulting increase of total IgG, or the switching to 
an IgG subclass that promotes disease progression, could mean the difference 
between resistance and susceptibility.  Another question raised by these data,  
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Figure 17. Reconstitution of JH Mice with C57BL/6 Sera. Lesion size of BALB/c mice 
(closed circles) and JH mice (open circles) was compared to JH mice given 200 µl antisera to 
L. major from C57BL/6 mice (open triangles) and JH mice given 200 µl antisera to L. major 
from BALB/c mice (closed triangles) on days 1, 7 and 14.  Parasite burdens (inset) were 
determined by limiting dilution. Error bars represent the standard deviation of the mean of 5 
determinations.  This experiment is representative of 3. 
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is whether the presence of IgG alone is sufficient for increased disease, or 
whether the presence of IgG must be coupled with an ongoing Th2 response 
to cause disease exacerbation.  
 
Disease in C57BL/6 Mice is Not Affected by BALB/c Serum 
We examined whether the addition of BALB/c α-L. major antisera 
could affect the progression of leishmaniasis in the normally resistant 
C57BL/6 strain of mice.  Two groups of C57BL/6 mice were infected with 
identical amounts of parasites, with or without the addition of BALB/c 
immune sera.  The passive administration of polyclonal α-L. major antiserum 
to C57BL/6 mice had essentially no effect on lesion progression (Figure 18, 
open circles).  These mice developed lesions with a similar size and kinetics 
as the control mice that received no antisera.  Furthermore, the two groups of 
mice had similar numbers of parasites within their lesions at the conclusion of 
the observation period (Fig. 18, inset).  Thus, unlike the JH mouse, the 
addition of BALB/c antisera to C57BL/6 mice was not capable of influencing 
disease outcome.  This could be due to the inherent differences in the immune 
responses mounted by these mice.  Since C57BL/6 mice mount a robust Th1 
response and are capable of controlling infections with L. major, the addition 
of antibody may not be enough to overcome this genetic tendency toward an 
inflammatory response.  These data suggest that IgG is required for disease 
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 Figure 18. Reconstitution of C57BL/6 Mice with BALB/c Sera. Lesion size of C57BL/6 
mice (closed circles) was compared to C57BL/6 mice given 200 µl antisera to L. major 
from BALB/c mice (open circles) on days 1, 7 and 14.  Parasite burdens (inset) were 
determined by serial dilution. Error bars represent the standard error of the mean of 3 
separate experiments with a minimum of 5 mice per group. 
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susceptibility, as shown in the JH model, but it may not be sufficient to 
overcome the inherent resistance of C57BL/6 mice. 
 
IgG Titers in Resistant and Susceptible  Strains 
The administration of BALB/c derived, but not C57BL/6 derived, α-L. 
major antisera influenced the course of L. major infections in JH mice.  This 
suggests a fundamental difference in the antisera of these animals, which leads 
to the difference in disease severity.  Consequently we examined a possible 
difference in the IgG titers of these animals.   
Infected C57BL/6 and BALB/c mice were bled, and their serum isolated.  A 
serial dilution of the sera was plated in 96 well plates, and L. major specific 
serum IgG levels, for total as well as isotype subclasses (IgG1, IgG2a, IgG2b, 
IgG3), were determined by ELISA.  IgG titers were consistently higher in L. 
major susceptible BALB/c mice, than in resistant C57BL/6 mice (Figure 19).    
In 7 separate experiments, the total L. major specific IgG titers were 2.75 x 
105 ± 1.65x 105 for BALB/c, and 1.15 x 105 ± 1.74 x 105 for C57BL/6 mice. 
While all BALB/c IgG titers were higher than those of C57BL/6 mice, the 
titers of subclasses IgG1 and IgG2a were found to be statistically significant 
using the Student’s t test.  In 7 separate experiments, IgG1 and IgG2a titers 
were 1.11 x 105 ± 8.46 x 104 and 1.23 x 105 ± 1.19 x 105 respectively for 
BALB/c and 5143 ± 4180 and 8714 ± 1.32 x 104 respectively for C57BL/6 
mice.  These data demonstrate that the circulating α-L. major titers are 22 fold  
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Figure 19. The Circulating α-L. major IgG Titers of Infected C57BL/6 vs BALB/c 
Mice. Sera were isolated from infected BALB/c or C57BL/6 mice. Titers of specific IgG 
subclasses were determined using ELISA. The mean of 5 separate determinations is 
represented by a solid bar. The circulating titers of total α-L. major IgG (IgG1, IgG2a, 
IgG2b, IgG3) for BALB/c mice (closed bar) and C57BL/6 mice (open bar) are shown in the 
inset graph. 
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higher for IgG1 and 14 fold higher for IgG2a in susceptible BALB/c mice, 
relative to resistant C57BL/6 mice.   
Amastigotes are known to be coated in host IgG, and consequently we 
examined whether surface IgG on lesion derived amastigotes mirrored the 
relative titers of circulating serum IgG.  L. major amastigotes were isolated 
from the footpads of BALB/c and C57BL/6 mice, and stained for the presence 
of surface IgG.  FITC conjugated antibodies were utilized to allow for the 
quantitation of total, as well as the specific isotype subclasses.  Flow 
cytometric analysis provided a direct comparison between and within the 
strains.  Amastigotes isolated from BALB/c footpad lesions had consistently 
higher levels of IgG on their surfaces (Figure 20).  In 5 separate experiments, 
the mean fluorescence intensities of amastigote surface IgG from BALB/c 
mice were determined to be statistically significant in all four subclasses using 
the Student’s t test.  Total IgG, IgG1 and IgG2a titers were 842 ± 223, 901 ± 
628 and 1000 ± 262 respectively for BALB/c, and 437 ± 183, 114 ± 70 and 99 
± 52 respectively for C57BL/6 mice.   
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Figure 20. Composition of IgG Sublasses on the Surface of Lesion Derived L. major 
Amastigotes. Amastigotes were isolated from the footpads of BALB/c and C57BL/6 mice. 
These amastigotes were stained for the presence of IgG on their surfaces.  Total IgG and its 
various subclasses were quantitated by flow cytometry.  (A) The mean fluorescent intensity of 
BALB/c and C57BL/6 subclasses are plotted. The mean of 5 determinants is plotted as a solid 
bar. (B) Flow profiles of BALB/c (blue line) and C57BL/6 (red line) are compared to the 
unstained control (black line). These profiles are representative of 5 separate experiments. 
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Amastigote Induced Macrophage Cytokine Profile Differs Between Strains 
Lesion derived amastigotes, which are coated in host IgG, coupled 
with an inflammatory stimulus such as LMW-HA, induce the production of 
IL-10 from macrophages.  This is an IgG dependent effect because axenically 
grown amastigotes, which are grown in cell free culture and thus lack surface 
IgG, are unable to induce macrophages to produce IL-1072.  The original 
observations showing IL-10 production by amastigotes were determined using 
lesion derived amastigotes isolated from BALB/c mice.  It had never been 
tested using amastigotes isolated from the resistant C57BL/6 strain.  
Consequently we examined the ability of C57BL/6 lesion derived amastigotes 
to induce the production of IL-10 from macrophages.   
When lesion derived L. major amastigotes isolated from BALB/c 
footpads were added to BMMφ from BALB/c mice, macrophages shut off the 
production of IL-12, and secreted high levels of IL-10.  Amastigotes derived 
from the lesions of C57BL/6 mice, however, were unable to completely 
abrogate the production of IL-12, and induced only modest levels of IL-10 
(Figure 21).  To ensure that this response was a direct result of the differences 
in the lesion derived amastigotes, and not an artifact of the origin of the 
BMMφ, we repeated the experiment using BMMφ isolated from C57BL/6 
mice.   
Similar to the previous experiment, L. major amastigotes isolated from 
BALB/c mice induced the C57BL/6 derived macrophages to shut off 
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Figure 21.  In vitro Cytokine Production of BALB/c vs C57BL/6 Derived Footpad 
Amastigotes.   Lesion-derived L. major amastigotes from either BALB/c or C57BL/6 mice 
were added to BALB/c bone marrow derived macrophages (10:1) in the presence of 
inflammatory low molecular weight hyaluronic acid (LMW-HA).  Supernatants were harvested 
24 hrs later and cytokines IL-12 (closed bars) and IL-10 (open bars) were measured by ELISA. 
Error bar represent 3 determinations. This experiment is representative of 4. 
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production of IL-12 and secrete high levels of IL-10.  Similar to the previous 
experiment, amastigotes isolated from the lesions of C57BL/6 mice failed to 
shut off production of IL-12 and induce IL-10 production (Figure 22).  These 
data suggest that amastigotes isolated from BALB/c lesions, but not those 
isolated from C57BL/6 lesions, are capable of altering the cytokine profile of 
macrophages, regardless of macrophage origin.  This observation, along with 
our preceding experiments, demonstrates the differences in IgG titers and 
amastigote surface IgG between susceptible BALB/c and resistant C57BL/6 
mice.     
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Figure 22.  In vitro Cytokine Production of BALB/c vs C57BL/6 Derived Footpad Amastigotes.   
Lesion-derived L. major amastigotes from either BALB/c or C57BL/6 mice were added to C57BL/6 
bone marrow derived macrophages (10:1) in the presence of inflammatory low molecular weight 
hyaluronic acid (LMW-HA).  Supernatants were harvested 24 hrs later and cytokines IL-12 (closed 
bars) and IL-10 (open bars) were measured by ELISA. Error bar represent 3 determinations. This 
experiment is representative of 4. 
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Discussion 
Murine Leishmania spp. infections have been extensively studied.  In 
response to L. major, C57BL/6 mice mount a Th1 response, leading to 
activation of macrophages and resolution of infection.  BALB/c mice mount 
an inappropriate Th2 response, blocking macrophage activation, leading to 
uncontrolled parasite replication and disease susceptibility.  These responses 
against L. major have been exploited, and yielded valuable data, which has 
furthered the knowledge of the Th1/Th2 paradigm.   
Resistance to L .major in murine infections is dependent upon a Th1 
response.  These responses are characterized by the production of IFN-γ.  In 
response to antigen, classically activated macrophages produce high levels of 
IL-12.  This IL-12 stimulates the production of IFN-γ from CD4+ Th1 cells, 
and CD8+ T cells.  The increase in the production of IFN-γ allows 
macrophages to become properly activated, and thus induces the destruction 
of phagocytosed microbes.  IFN-γ also stimulates the differentiation of naïve 
T cells into the Th1 subset.  IFN-γ  not only stimulates a Th1 environment, but 
blocks the production of Th2 cytokines, and prevents the proliferation of naïve 
T cells into the Th2 subset.  B cells induce class switching to IgG2a in 
response to IFN-γ, and inhibit switching to the Th2 subclass, IgG1. 
Susceptibility to L. major is associated with a Th2 response.  IL-4 is 
the hallmark cytokine of this response, and induces naïve CD4+ T cells to 
develop into Th2 cells.  IL-4 promotes the production of IgG1 from B cells, 
and class switching to IgE, while inhibiting the production of the IgG2a and 
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IgG3 sublasses of IgG.  The abrogation of IL-4 during L. major infections, 
either by IL-4 knockout113;114 or a monoclonal antibody to IL-4111;112, has 
demonstrated its importance in disease susceptibility.  Another Th2 related 
cytokine, IL-10, has also been shown to be important in the susceptibility to L. 
major murine infections72;139;189.  IL-10 inhibits the activation of 
macrophages, and blocks the production of IL-12.  This deactivation of 
macrophages leaves them unable to kill the ingested L. major parasites, which 
are now free to replicate unchecked, leading to increased susceptibility. 
We previously showed a role for IL-10 and IgG in the disease 
progression of L. major infections189.  The presence of IgG, in otherwise 
resistant mice, lead to the formation of immune complexes that influenced 
disease by inducing the production of IL-10 from macrophages.  As discussed, 
IL-10 blocks macrophage activation and the production of IL-12.  IL-12 is 
needed for enhanced IFN-γ production, and a biasing toward the protective 
Th1 response.  Thus IgG immune complexes, and the subsequent production 
of IL-10, could be the key in determining the path of the murine immune 
response.  The goal of these experiments was to examine possible differences 
in the IgG between resistant and susceptible mice.   
Previous work in the Leishmania field has examined the role that B 
cells and IgG play in disease progression.  The role of B cells, and the 
subsequent lack of IgG, has been met with mixed reviews.  The examination 
of a role for B cells, and/or IgG, in leishmaniasis has been well documented in 
the literature97;149;157;158;161;163;165;166;181;182;189.  While most agree that there is 
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indeed a role for B cells and/or IgG, the mechanisms of action proposed, vary 
greatly.  Brown and Reiner are the lone group to determine that B cells play 
no roll in L. major infections165.  Using µMT mice from both the BALB/c and 
C57BL backgrounds, they determined that infections with L. major remained 
unchanged in the absence of B cells.  However, as early as 1984, Sacks, et 
al.demonstrated that B cells were required for the susceptibility of BALB/c 
mice to L. tropica and L. mexicana infections149.   
While several groups acknowledge a role for IgG in 
leishmaniasis97;163;166;182, we are the only group to offer a definitive 
mechanism and establish this role in immune complex formation and 
subsequent induction of macrophage IL-10189.  In light of our previous 
observations showing the role of IgG in disease progression, we examined the 
IgG titers in resistant mice and compared them to the IgG titers of susceptible 
mice.  In these experiments, α-L. major antisera from BALB/c mice, but not 
from C57BL/6 mice, was able to influence the progression of L. major 
infections in JH mice.  These data were interesting because they reiterated the 
effect of BALB/c antisera on JH mice.  Despite this however, antisera from 
C57BL/6 mice could not induce susceptibility to disease.  This gives further 
evidence of a distinct difference in the antisera, most likely in IgG titers, of 
resistant and susceptible strains of mice.  In accordance with this theory, we 
determined that L. major infected BALB/c mice had consistently higher titers 
of circulating IgG, as well as higher levels of IgG on the surface of their lesion 
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derived amastigotes, than C57BL/6 mice also infected with L. major in the 
same manner.   
 IgG contributes to the progression of L. major infections by forming 
immune complexes.  These complexes ligate the FcγRs on macrophages, 
altering their cytokine production.  These macrophages shut off the production 
of the inflammatory cytokine IL-12, and begin to produce large amounts of 
the anti-inflammatory cytokine IL-10.  This change in cytokine production 
leads to the development of a Th2 environment, and prevents the activation of 
macrophages, which is crucial to the eradication of the parasite.  L. major 
amastigotes derived from BALB/c lesions were able to shut off production of 
the inflammatory cytokine IL-12 from macrophages and induce them to 
produce high levels of the anti-inflammatory cytokine IL-10.  Interestingly, 
amastigotes isolated from the lesions of C57BL/6 mice were unable to induce 
this response.   
Without macrophage activation, L. major amastigotes are able to 
replicate unchecked inside the macrophage, and develop into rapidly 
progressing lesions which eventually lead to metastasis and loss of infected 
extremities in mice.  Thus, IgG exacerbates disease by inducing the 
production of IL-10 from macrophages.  Therefore, high levels of IgG on the 
surface of BALB/c derived amastigotes could be a possible explanation of the 
production of IL-10 from macrophages stimulated with these parasites, and 
the failure of low level IgG C57BL/6 amastigotes to induce this similar 
response.   
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It is possible that high antibody titers are needed for the ligation of 
FcγRs, leading to the production of IL-10 from macrophages.  Also, this 
alteration of cytokine secretion, allows for the deactivation of macrophages 
and ultimately, the continued survival of the Leishmania parasites residing 
within them.  The pronounced differences between the titers of the specific 
subclasses of IgG, IgG1 and IgG2a, between the resistant and susceptible 
strains suggests that IL-10 induction could be the result of a specific subclass, 
rather than total amounts of IgG.  A new FcγR, FcγRIV, was recently 
discovered by Ravetch and colleagues8, which interacts exclusively with 
IgG2a and IgG2b.  The interaction of IgG1 with FcγRIII, along with the 
affinity of FcγRIV for IgG2a and IgG2b, may account for their protective and 
pathogenic activities.  Future exploration of this FcγR-IgG interaction may 
provide additional insight into any role this phenomenon may play in the 
resistance or susceptibility of mice to L. major infections. 
We have thus far been unable to determine whether it is the quantity of 
IgG produced, or a specific isotype, which is responsible for our observations.  
Thus, we are currently working on purifying each IgG subclass from the α-L. 
major antisera of both C57BL/6 and BALB/c mice.  In doing this, it will make 
it possible to determine whether it is simply an abundance of IgG that causes 
disease susceptibility in BALB/c mice, or whether the increased production of 
a specific IgG subclass is responsible.  Currently, we see the most dramatic 
increase in the titers of IgG1 and IgG2a of BALB/c mice, when compared to 
C57BL/6 mice.  This is also an interesting observation due to the opposing 
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responses normally associated with these subclasses.  IgG1 is a predominantly 
Th2 subclass, induced by IL-4 driven class switching of B cells.  In contrast, 
IgG2a is a predominantly Th1 subclasses, induced by IFN-γ.  Thus, it is 
surprising to see the titers of both subclasses increased in the robust Th2 
response associated with BALB/c disease.   
The increase in opposing IgG subclasses reiterates that more may be 
involved than the simple upregulation of IgG sublclasses.  Therefore, we 
cannot rule out the possibility of a specific FcγR being involved.  FcγRI and 
FcγRIII are known to induce the production of IL-10 upon ligation with 
immune complexes20;23;24, and FcγRIII is known to associate predominantly 
with IgG1.  Very little is known about FcγRIV, as it was only recently 
discovered8, however it interacts with IgG2a and IgG2b exclusively.  The 
distinct and opposing IgG subclass specificities may play a role in shaping the 
immune responses mounted by resistant and susceptible strains of mice.  
These different FcγRs, along with their IgG subclass preferences, must be 
examined further to determine what role, if any they play in the IgG mediated 
exacerbation of L. major infections.   
Additionally, human as well as murine monocytes studies will be 
undertaken to determine the role, and specificities, of IgG and FcγRs involved 
in disease.  It is currently known that human visceral disease results in a 
marked increase of IgG titers145;147;185;189, and the production of IL-1074;138;189.  
In fact these two determinants are actually predictive of disease.  Due to the 
similarities between human visceral and BALB/c L. major infections (high 
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IgG responses, increased IL-10 production), we proposed that the BALB/c 
model of L. major infection is comparative to human visceral disease189.   
Control monocytes from healthy donors, or naïve BALB/c mice, as 
well as monocytes from patients with confirmed visceral disease, or L. major 
infected BALB/c mice, will be analyzed based on their expression of FcγRIII.  
We would expect to see an upregulation of FcγRIII in infected samples, thus 
correlating with the published reports of increased IL-10, and susceptibility to 
disease.  Additionally, the same experiment repeated in monocytes isolated 
from humans infected with cutaneous forms, such as L. major, could be used 
in comparison with C57BL/6 L. major infections.  The low IgG titers, as well 
as the ability of C57BL/6 mice to control and cure L .major infections would 
make it an ideal model for the comparison of human cutaneous disease.  These 
data will help provide a distinction between healthy and infected monocytes 
and provide further insight into the populations of monocytes that are present 
during ongoing disease.   
The ability of BALB/c immune serum, which has higher titers of L. 
major specific IgG, but not C57BL/6 serum with low titers of L. major 
specific IgG, to influence the progression of leishmaniasis in JH mice suggests 
the involvement of IgG in susceptibility.  Although the presence of L. major 
specific IgG exacerbated disease in JH mice, which are on the susceptible 
BALB/c background, it was unable to influence disease in L. major resistant 
C57BL/6 mice.  These data suggest that while IgG induces the production of 
IL-10 and furthers the Th2 response necessary for susceptibility to 
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leishmaniasis, it cannot overcome the innate resistance and robust Th1 
response mounted by the C57BL/6 strain.   
This suggests that both the presence of IgG is required, but not 
substantial enough to increase disease alone.  Additionally, the resistance of 
BALB/c IL-4-/- mice113, furthers the idea of the necessity of both a sustained 
Th2 response, and the presence of IgG.  This observation, along with our data, 
would suggest that the development of a Th2 response, along with the 
presence of IgG, is imperative to the development of lesions and the 
exacerbation of disease.  Additionally, we would like to identify the IgG 
subclass, if there is one, responsible for inducing the production of IL-10, 
because it could lead to a therapeutic antibody to increase IL-10 levels during 
autoimmunity.   
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